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MARK4 (MAP/Microtubule Affinity-Regulating Kinase 4) is a serine-threonine kinase that 
phosphorylates the Microtubule Associated Proteins (MAPs) taking part in the regulation of 
microtubule dynamics involved in cell cycle regulation and proliferation. MARK4 is 
ubiquitously expressed and two different isoforms are produced through alternative splicing: the 
constitutive MARK4S, consisting of 18 exons, and the alternative MARK4L encoded by a 
transcript that undergoes skipping of exon 16 and consequent frameshift of the reading frame. 
The differential expression of the two MARK4 isoforms in human tissues and, particularly in the 
Central Nervous System, point to their not fully overlapping roles. MARK4S is predominant in 
normal brain and differentiated neurons and has been associated to cell differentiation, while 
MARK4L is mainly expressed in neural progenitors and is up-regulated in hepatocarcinoma and 
glioma, suggesting a function of this isoform in cell proliferation. In glioma and glioblastoma-
derived cancer stem cells (GBM CSCs), we pointed out an imbalance between the two MARK4 
isoforms, directly proportional to cell de-differentiation and tumour grade. Such imbalance is 
triggered by decrease in MARK4S expression, associated with overexpression of MARK4L. The 
MARK4 expression profile observed in glioma matches that observed in mouse neural stem cells 
(NSCs). Moreover, MARK4L has been found expressed in the embryonic ventricular zone and 
adult sub-ventricular zone, both well known regions of neurogenesis, suggesting that the balance 
between the two MARK4 isoforms is critical for neural differentiation and proliferation. 
Therefore, in glioma a subverted MARK4L/MARK4S ratio may contribute to cellular de-
differentiation and proliferation during gliomagenesis.   
Having ruled out mutations or copy number loss/gain as cause of deregulation of MARK4 
expression in glioma, we hypothesised that alterations at the post-transcriptional level, possibly 
in alternative splicing, might be at the origin of the observed MARK4 isoforms imbalance. 
MARK4L total mRNA evaluation by real-time PCR in glioma tissue samples and GBM CSCs, 
failed to reveal differences in the overall expression of the kinase, even in the presence of 
significantly different expression levels of the two isoforms, supporting the hypothesis of an 
alteration in alternative splicing at the root of MARKL/MARK4S imbalance in glioma.  
Alternative splicing is the most important mechanism in generating proteomic diversity from a 
limited number of genes. Alternatively spliced isoforms expression is thinly controlled according 
to specific cells signalling and developmental stages by a complex interplay between 
spliceosome and splicing regulatory factors, which can be grouped into the two main classes of 
SR (serine-arginine rich) and hnRNP (heterogenous nuclear ribonucleoprotein) proteins. The 
intrinsic plasticity of alternative splicing in proteome modelling, make sthis process a tempting 
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target for cancer cells to enhance the production of protein isoforms sustaining tumour growth 
and spread. Protein isoforms produced from exon skipping, like MARK4L, are commonly found 
enriched in cancer, including glioma, as a consequence of hnRNP protein overexpression. We 
thus performed bioinformatic analysis to identify putative binding sites for hnRNP proteins in 
MARK4 pre-mRNA. Among the predicted putative binding sites for hnRNPs, three binding 
motifs for PTB (polypyrimidine-tract binding protein) appeared of particular interest, given the 
role of PTB in regulating neural stem cells proliferation and differentiation and its established 
involvement in glioma, where it is aberrantly overexpressed and induces the expression of 
protein isoforms produced by exon skipping. We found two putative PTB binding sites in intron 
15 (IVS15) and one in intron 16 (IVS16). One of the two identified regulatory sequences in 
IVS15 is embedded in a polypyrimidine rich context and may represent a high affinity PTB 
binding site that could favour MARK4 exon 16 skipping by competition with U2AF65 or, 
together with the other PTB binding sites, by polymerisation or intron looping. A functional role 
of these sites is also suggested by the high sequence conservation between human and mouse.  
Western blot analysis showed a significant overexpression of PTB in our astrocytoma and 
glioblastoma samples, correlating with MARK4L expression and thus with tumour grade and 
cell de-differentiation. Moreover, GBM CSCs, both undifferentiated and differentiated, showed 
high levels of PTB coherently with the nearly exclusive expression of MARK4L. However, 
while NSCs show undetectable levels of MARK4L upon differentiation, in differentiated GBM 
CSCs high expression levels of MARK4L are maintained possibly sustained by PTB 
overexpression.  
We then performed minigene splicing assays to identify the specific sequences involved in 
MARK4 alternative splicing. We focused our attention on the polypyrimidine tract in MARK4 
VS15 and constructed a MARK4 splicing minigene by cloning, in a mammalian expression 
vector, the MARK4 genomic region comprising exons 15, 16 and 17 and IVS15 and IVS16. 
Sequential deletions of different IVS15 portions revealed that the last 87 nucleotides of intron 15 
contain a functional intronic splicing silencer (ISS). However, mutagenesis of the PTB binding 
site contained in this region did not affect minigene splicing, suggesting that PTB may be 
involved in MARK4 splicing by binding to a non canonical ISS or by cooperating with other 
identified PTB binding sites. Moreover, electrophoretic mobility shift assays (EMSA) 
highlighted a specific shifted band probably due to the interaction of splicing factors with 
MARK4 pre-mRNA. Mass spectrometry experiments are in progress aiming at identifying the 
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protein(s) bound to MARK4 IVS15, and seem to confirm the presence of PTB in the shifted 
band.  
The achieved data, suggest that PTB overexpression in glioma may favour MARK4L expression 
causing the observed imbalance between the two MARK4 isoforms, featuring alternative 
splicing as an oncogenic mechanism that through the fine tuned regulation of MARK4 isoforms 
may foster proliferation and de-differentiation in glioma. 
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1.1 Splicing  
Pre-mRNA splicing is a fundamental process regulating gene expression in eukaryotes, given the 
split nature of eukaryotic genes. Intron removal and the consequent exon joining is catalysed by 
the spliceosome, a ribonucleoprotein complex that assembles on the pre-mRNA in different 
complexes. Spliceosome conformation and composition are dynamic, allowing accuracy and, at 
the same time, flexibility of the splicing machinery. In eukaryotes, there are at least two types of 
spliceosomes, U2-dependent spliceosome and the rare U12-dependent spliceosome, that differ in 
the regulatory sequences and the proteins involved. Some exons are constitutively spliced being 
included in every mature mRNA produced from a given pre-mRNA, while many are 
alternatively spliced to generate, from the same pre-mRNA, multiple splicing isoforms 
containing a different combination of exons. Data from high-throughput RNA sequencing of 
transcriptomes indicate that at least 95% of human multi-exon genes undergo alternative splicing 
(Pan et al., 2008; Wang et al., 2008) and the frequency of alternative splicing increases with cell 
types and species complexity (Barbosa-Morais et al., 2012; Nilsen and Graveley, 2010). 
Therefore alternative splicing allows the production of protein isoforms of differing and even 
opposing functions from a single gene, featuring as the major contributor of proteomic diversity. 
Indeed, through the alternative splicing mechanism, isoforms expression is thinly regulated 
during development and according to specific cell signalling. The key role of alternative splicing 
in different cellular processes is confirmed by the fact that 50% of human genomic diseases 
arises from mutations in the consensus splice site sequences or in other auxiliary sequence 
elements. Moreover, the plasticity that characterises the mechanism of alternative splicing and its 
crucial involvement in proteome remodelling offers the opportunity to cancer cells to subvert the 
process and induce the expression of proteins that sustain tumour growth and spread.  
 
1.1.1 Core splicing signals and the catalytic steps of splicing  
As other mechanisms implicated in the regulation of gene expression, splicing involves both cis- 
and trans-acting components represented by specific sequences on the pre-mRNA and 
ribonucleoprotein factors, respectively. It is often very difficult to make a clear distinction 
between “constitutive” and “alternative” splicing components and usually the relative functional 
strengths of splice sites and RNA-protein interaction determine the exon fate. Constitutive 
splicing concerns short conserved sequences at the 5’ (GU) and 3’ (AG) splice sites and at the 
branch site (A nucleotide in a specific context YNYURAY) that provides information for the 
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identification of intronic sequences that have to be removed from pre-mRNA (Figure 1).  
 
 
Figure 1. Consensus sequences for 5’ splice site (donor), 3’ splice site (acceptor) and branch site (Srebrow and 
Kornblihtt, 2006). 
 
Additional regulatory sequences, defined exonic and intronic splicing enhancers (ESEs and 
ISEs) or silencers (ESSs and ISSs), modulate both constitutive and alternative splicing through 
the binding of protein factors that either stimulate or repress the assembly of the spliceosomal 
complexes at adjacent splice sites (Smith and Valcarcel, 2000). The recognition and assembly of 
splicing factors to both splice-site recognition and non-splice site sequences (ESE/ISE and 
ESS/ISS) constitute an integrated splicing code that ensures the high fidelity of the splicing 
process. 
Introns are removed by the spliceosome in two consecutive transesterification reactions (Figure 
2A and B). The U2-dependent spliceosome is composed of U1, U2, U5 and U4/U6 small nuclear 
ribonucleoproteins (snRNPs), in addition to numerous non-snRNP proteins. Each snRNP is 
formed by small nuclear RNA (snRNA), a common set of seven Sm proteins (B/B’, D3, D2, D1, 
E, F and G) and a variable number of particle-specific proteins (Will and Lührmann, 2006). 
Nascent RNA transcribed from RNA polymerase II is bound by the earliest spliceosomal 
complex, the E complex. In particular, the U1 snRNP is recruited to the 5’ splice site while 
SF1/BBP (branch site binding protein) and U2AF, all non-snRNP factors, bind to the branch site 
and the downstream polypyrimidine tract, respectively. Subsequently, the U2 snRNP associates 
with the branch site forming the A complex, also defined pre-spliceosome. The U4/U6.U5 tri-
snRNP is recruited to form the catalytic B complex. Following RNA-RNA and RNA-protein 
interaction rearrangements destabilise the U1 and U4 snRNPs giving rise to the activated 
spliceosome or the B
act
 complex (Figure 2A) (Will and Lührmann, 2011; Smith and Valcárcel, 
2000). The activated B complex catalyses the enzymatic reactions that allow intron excision and 
exons joining. The 2’OH group of the branch adenosine in the intron, through a nucleophilic 
attack on the 5’ splice site, cleaves this site and ligates the 5’-end of the intron to the branch 
adenosine, resulting in the formation of a lariat structure (Figure 2B). The 3’ splice site is then 
attacked by the 5’ end of the exon, leading to the 5’ and 3’ exons joining and the release of the 
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intron. At the end of the catalytic process the spliceosome disassembles and other heterogeneous 
ribonucleoproteins (hnRNP) bind to the mature mRNA to facilitate nucleocytoplasmic export 
(Will and Lührmann, 2011). Even if proteins that constitute the spliceosomal complex have been 
always considered the main actors of splicing, it has been recently proposed that pre-mRNA 
catalysis is at least partially RNA-based with a mechanism similar to that of self splicing introns, 
with U2 and U6 playing key roles (Wachtel and Manley, 2009).  
 
 
Figure 2. Pre-mRNA splicing catalysed by U2-dependent spliceosome. A) Assembly and disassembly of the U2-
dependent spliceosome. B) Schematic representation of the two transesterification reactions of pre-mRNA splicing 
(Adapted from Will and Lührmann, 2011). 
 
1.1.2 Alternative splicing 
The fidelity of the splicing process mostly resides in the recognition of splice sites. Even if the 
spliceosome, with the dynamic and thinly controlled assembly of different components, ensures 
the correct identification of constitutive splice sites, a certain degree of freedom is enabled. The 
splicing mechanism has actually evolved to increase proteome diversity in the presence of a 
relative small number of genes. Therefore, alternative splicing generates different mRNAs 
encoding different protein products, increasing the coding capacity of genes. Weak splice sites, 
that deviate from the consensus sequence, are the key players of alternative splicing. They show 
less affinity for the spliceosome since their sequence differs from the canonical one. A second 
A
B
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class of cis-acting elements enhances the recognition and use of weak splice sites: enhancers and 
silencers of splicing. These are short (maximum 10 nucleotides) conserved sequences placed in 
exons or introns, either isolated or in clusters, that stimulate or inhibit the use of weak splice 
sites. Exonic/intronic splicing enhancers (ESE/ISE) typically bind members of the Ser/Arg-rich 
(SR) family of proteins, while splicing silencers (ESS/ISS) are binding sites for heterogeneous 
nuclear ribonucleoproteins (hnRNPs) (Figure 3). 
 
Figure 3. Schematic representation of exon definition by ESE/ISE and ESS/ISS. SR (red) and hnRNP (bleu) 
proteins bind to enhancer and silencer sequences and target components of the spliceosome (green) associated with 
the 5’ and 3’ splice sites of the alternative exon favouring or inhibiting the recognition and use of these weak splice 
sites (Kornblihtt et al., 2013).  
 
These splicing activators and repressors commonly affect the formation of the E complex and 
result in one of the five observed alternative splicing events (Figure 4): i) cassette exons are 
single exons that can be included in the mRNA or skipped. They can also be subdivided into 
“skipped” or “cryptic” exons on the basis of whether the main isoform includes or excludes the 
exon, respectively; ii) mutually splicing events, instead, implicate the selection of one exon 
among an array of two or more alternative exons; iii) competing 5’ and 3’ splice sites are “exon 
modifications” that result in exons of different sizes. Other rarer alternative splicing events 
include retained introns, alternative splicing associated with alternative promoters and alternative 
3’-end processing (Matlin et al., 2005). 
 
Figure 4. Alternative splicing patterns reported so far (Matlin et al., 2005). 
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1.2 Regulation of alternative splicing by SR and hnRNP proteins 
Regulatory SR proteins and hnRNPs usually bind to short degenerate sequences, frequently 
represented in the genome, and a single binding site is generally sufficient to define splice site 
use (Singh and Valcárcel, 2005). Splicing enhancers are usually recognized by SR proteins, 
leading to the recruitment of U1 and U2 snRNPs and U2AF to the pre-mRNA. Thus, SR proteins 
induce RNA-RNA and RNA-protein interactions that allow splice sites definition and correct 
positioning of the spliceosome for the catalysis of splicing reactions. Splicing silencers are, 
instead, recognised by hnRNPs that antagonise the effect of SR proteins but their mechanism of 
action are less known compared to SR proteins (Busch and Hertel 2012). Modulation of SR and 
hnRNP proteins expression thus allows developmentally, tissue specific and signalling regulated 
alternative splicing. 
1.2.1 SR proteins 
SR proteins were originally discovered in Drosophila in the early 1990s (Fu 1995). They have a 
modular structure composed of one or two RRM (RNA recognition motif) at the N-terminus, that 
confers to the protein the RNA-binding specificity, and a C-terminal RS domain (serine-arginine 
rich) that promotes protein-protein interaction needed for spliceosome recruitment (Wu and 
Maniatis 1993; Kohtz et al., 1994). SR proteins function in both constitutive and alternative 
splicing favouring the inclusion of alternative exons in the mature mRNA (Long and Cáceres, 
2009). Three different mechanisms of action have been proposed for SR proteins (Figure 5). In 
the “recruitment model”, SR proteins bound to ESEs recruit and stabilise the interactions of U1 
snRNP with the 5’ splice site and of U2AF65 with the 3’ splice site (Graveley et al., 2001). 
According to the “inhibitor model”, instead, enhancer-bound SR proteins antagonise the negative 
effect of hnRNPs (Zhu et al., 2001). SR proteins may also get organised in a network across 
introns to juxtapose the 5’ and 3’ splice sites and loop out the intron (Wu and Maniatis, 1993).  
The functions of SR proteins go beyond constitutive and alternative splicing: SR proteins play a 
role also in mRNA nuclear export, nonsense-mediated decay (NMD) and translation (Huang and 
Steitz, 2005). SR proteins have a nuclear localisation signal and accumulate in nuclear speckles 
(Lamond and Spector, 2003). However, a subset of SR proteins shuttle continuously between the 
nucleus and the cytoplasm and function in the nucleocytoplasmic export of mRNA by interacting 
with the nuclear export apparatus (Cáceres et al., 1998). SR proteins have also been implicated 
in the NMD pathway. In particular, overexpression of SF2/ASF, SC35 and SRp40 SR proteins 
was found to enhance NMD (Zhang and Krainer, 2004). Moreover, a subset of SF2/ASF are 
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implicated in pre-mRNA splicing of kinases involved in translation, including MNK2 and S6K1 
(Karni et al., 2007). SR proteins have also been demonstrated to directly affect translation, by 
interacting with polyribosomes, and IRES-mediated translation (Sanford et al., 2004; 
Michlewski et al., 2008).  
 
 
Figure 5. Mechanisms of action of SR proteins. A) Recruitment model, B) inhibitor model and C) network of 
protein-protein interactions to loop out the intron (Long and Cáceres, 2009). 
 
1.2.2 hnRNP proteins 
HnRNPs are modular proteins consisting of different domains connected by a liker domain. Each 
hnRNP contains at least one RNA-binding motif including an RNA recognition motif (RRM), a 
hnRNP K homology domain (KH) or an arginine/glycine-rich (RGG) box (Dreyfuss et al., 1993; 
Krecic and Swanson 1999). HnRNPs localise in the nucleus, but are excluded from the 
nucleolus, and most of them shuttle between the nucleus and cytoplasm (He et al., 2005). 
HnRNPs associate to the nascent pre-mRNA by binding to ESSs and ISSs and inhibit the use of 
3’ splice site or favour the use of more distal 5’ splice sites. HnRNPs generally antagonise the 
function of SR proteins (Martinez-Contreras et al., 2007). Binding of hnRNPs to ESSs or ISSs 
along the intron-exon junction limits the access of the splicesome to the splice sites and of SR 
proteins to splicing enhancer sequences (Mayeda and Krainer 1992) (Figure 6A). Binding of 
hnRNPs sterically blocks the binding ofU2 snRNP and inhibits spliceosome assembly (Tange et 
al., 2001) (Figure 6B). Moreover, binding of hnRNPs to both introns flanking the alternative 
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hnRNPhnRNP
A
B
C
exon allows interaction between hnRNPs and favours the looping out of the exon (Nasim et al., 
2002) (Figure 6C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Mechanisms of hnRNP-mediated splicing (adapted from He and Smith, 2009). 
 
In addition to pre-mRNA splicing, other important functions of these proteins include telomerase 
biogenesis/maintenance (Zhang et al., 2006), transcription (Xia 2005), nuclear import-export 
(Brumwell et al., 2002), cytoplasmic trafficking of mRNA (Ma et al., 2002), mRNA stability 
(Hamilton et al., 1999) and translation (Bonnal et al., 2005). As regards the roles in DNA 
stability hnRNPs seem to destabilise G-quartets structures, that are crucial for DNA replication, 
transcription and telomere maintenance (Fukuda et al., 2002). HnRNPs also take part in DNA 
replication. In particular, UP1 activates the DNA polymerase α, that synthesises an RNA-DNA 
primer and allows the formation of the Okazaki framgments during the synthesis of the lagging 
DNA strand (Chai et al., 2003). Moreover, hnRNP A1 interacts with DNA topoisomerase I, 
which cleaves one strand of duplex DNA, relaxing supercoiled DNA and then regulating DNA 
topology during replication, chromosome condensation and transcription (Gupta et. al, 1995). 
The role of hnRNPs in DNA metabolism also includes telomeres maintenance as hnRNPs 
associate with the 3’single-stranded telomeric extension and protect it from nuclease attack 
(Zhang et al., 2006). HnRNP proteins function as a bridge between the telomeric DNA template 
and the RNA component of telomerase. Furthermore, hnRNPs play a role in DNA repair. 
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HnRNP B1 associates with the DNA-dependent protein kinase that mediates DNA double-strand 
breaks repair (Iwanaga et al., 2005).  
Although hnRNPs preferentially bind to RNA, some of them have been demonstrated to 
associate with promoter sequences and thus regulate transcription. For example, hnRNP A1 
binds the promoters of c-myc, APOE, thimidyne kinase, γ-fibrinogen and vitamin D receptor 
genes, even if the mechanisms of action are unknown (Takimoto et al., 1993, Campillos et al., 
2003, Lau et al., 2000). Similarly to SR proteins, also hnRNPs are involved in the nuclear export 
of mRNAs, but the molecular mechanisms are not well understood. It has been supposed that 
hnRNPs may associate with components of the nuclear export complex (Michael et al., 1995). 
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1.3 Other levels of regulation of alternative splicing  
Alternative splicing is one of the most exploited mechanisms underpinning dynamic remodelling 
of the transcriptome according to specific cell signalling and developmental stages. Different 
regulatory networks have been identified that affect alternative splicing throughout physiological 
changes. Different observations support this fundamental role of alternative splicing: i) any 
modification at the transcriptional level is accompanied by a co-integrated post-transcriptional 
response; ii) physiological splicing modifications are finely tuned in a spatio-temporal manner; 
iii) splicing modifications that are associated with specific cell signalling are phylogenetically 
conserved; iv) genome-wide studies have revealed the presence of a set of genes that are 
regulated at the transcription level, with modification of mRNA expression without differences 
in the expression of splice variants, and a second set of genes characterised by changes in the 
expression of mRNA isoforms without changes in the total expression (Kalsotra and Cooper, 
2011). Therefore, the use of alternative exons can be controlled by the cells in a developmental, 
tissue-specific or pathology-specific stage. Different mechanisms and signal transduction 
pathways have been linked to the regulation of alternative splicing. In this context alternative 
splicing, transcription, chromatin structure and transduction pathways are integrated to ensure 
transcriptome dynamic changes according to cell requirements (Figure 7).  
 
 
Figure 7. Integrated model for the regulation of alternative splicing (Luco et al., 2011). 
 
1.3.1 Phosphorylation of splicing factors and related underlying transduction 
pathways  
The regulation of the phosphorylation status of splicing factors is crucial for the correct outcome 
of splicing patterns. Phosphorylation is, in fact, the main mechanism for regulating the activity 
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and the cellular localisation of SR and hnRNP proteins. Phosphorylation of splicing factors is 
carried on by different protein kinases, some specific and other involved in common signal 
transduction pathways that allow modulation of alternative splicing patterns according to 
external or internal cues. SR-protein specific kinases include SR-protein kinases (SRPKs) which 
regulate, in the nucleus, the release of SR proteins to the nucleoplasm from the nuclear speckles 
and, in the cytoplasm, their nuclear import (Yun and Fu, 2000; Wang et al., 1998). Cyclin-
dependent like kinases (CLKs) represent another class of SR protein kinases mainly involved in 
the regulation of SR proteins subcellular localisation (Naro and Sette 2013). 
Signal transduction pathways have also been found to regulate alternative splicing according to 
physiological and pathological stimuli. The Ser-Thr kinase AKT, for example, is a key 
component of the phosphoinositide-3-kinase-protein-kinase (PI3K) pathway and transduces the 
signals of growth factors and cytokines. It has been reported that AKT phosphorylates both SR 
and hnRNP proteins that contain, in the RS domain, multiple AKT phosphorylation consensus 
sequences (RXRXXS/T) (Obata et al., 2000) and is able to regulate the activity of the SRPKs, 
achieving the coordinated modulation of both activators and effectors (Zhou et al., 2012).  
Mitogen-activated protein kinases (MAPKs) are Ser-Thr kinases that control metabolism, 
proliferation, survival, differentiation and motility, through modulation of the protein activity 
and stability, and alternative splicing (Cargnello and Roux, 2011). Indeed, the RAS-RAF-MEK-
ERK pathway is involved in the inclusion of the alternative v5 exon in the CD44 mRNA upon T-
cell activation. Phosphorylation by ERK of the splicing regulator Sam68 reduces its affinity for 
U2AF65 and thus the recognition of the 3’ splice site (Matter et al., 2002).  
cAMP-dependent protein kinase (PKA) is another kinase with a well established role in the 
regulation of alternative splicing. First evidences on the involvement of PKA in the alternative 
splicing modulation, came from the observation that a fraction of the active subunit of the kinase 
translocates to the nucleus, colocalises with SRF2 and phosphorylates several SR proteins 
(Kvissel et al., 2007). Subsequently, several stimuli that lead to the increase in the amount of 
intracellular cAMP were shown to affect alternative splicing through phosphorylation of both SR 
and hnRNP proteins. For example, forskolin, that stimulates the synthesis of cAMP, modulates 
the inclusion of exon 10 in Tau mRNA (Shi et al., 2011). PKA also modulates alternative 
splicing of genes that are crucial for neuronal differentiation through the phosphorylation of 
hnRNP K. Phosphorylation increases the binding activity of hnRNP K to its target mRNAs in 
competition with the spliceosomal component U2AF65, impairing the recognition of the 3’ 
splice site and leading to the skipping of target exons (Cao et al., 2012).  
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Some other proteins were found to have an unexpected kinase activity towards splicing factors. 
Among these proteins DNA topoisomerase I has been shown to phosphorylate several SR 
proteins, even in the absence of a canonical ATP binding site (Labourier et al., 1998) and the 
dual activity of the DNA topoisomerase I may allow the coordination of DNA transcription and 
splicing. Also Aurora kinase A (AURKA) was demonstrated to be involved in the alternative 
splicing of BCL-X. AURKA positively regulates the expression of the antiapoptotic variant, 
BCL-XL through stabilisation of SRF1 splicing factor (Moore et al., 2010). 
1.3.2 Coupled transcription and splicing 
More than 20 years ago electron microscopy on Drosophila embryos provided the first evidence 
that splicing can occur cotranscriptionally (Beyer and Osheim, 1988). Cotranscriptionality of 
splicing was then demonstrated also in humans for the dystrophin gene (Tennyson et al., 1995). 
Cotranscriptionality does not mean that the two events are coupled, but only that splicing is 
committed or catalysed before transcription termination and release of mRNA. In this context, 
the transcription and the splicing apparatus interact with each other and one influences the 
outcome of the other. Efficient coordination of the two mechanisms is mainly achieved through 
modification of the promoter and by the C-terminal domain (CTD) of RNA polymerase II.  
Recent studies have actually highlighted that the type of promoter used to drive transcription by 
RNA polymerase II may impact alternative splicing (Cramer et al., 1997). Two models have 
been proposed. In the “recruitment model”, changes in the promoter architecture affect the 
recruitment of splicing factors to the nascent mRNA. Instead, in the “kinetic model”, the 
promoter structure influences RNA polymerase II elongation rate, so that the splicing machinery 
has more or less time to recognise and splice alternative exons (Kornblihtt, 2007).  
Targeted experiments highlighted that the rate of RNA synthesis affects its secondary structure 
that in turn affects splicing. Experimental data support the hypothesis of the so called “first 
come, first served” model of splicing (Aebi and Weissmann, 1987). In this model, slow 
elongation, favours the removal of the upstream intron of an alternative cassette exon before the 
removal of the downstream intron. In an alternative version of the same model slow elongation 
allows the recruitment of splicing factors to the upstream intron before the downstream intron is 
synthesised.  
The C-terminal domain (CTD) of RNA polymerase II provides an additional link between 
transcription and splicing. The CTD can undergo posttranslational modifications by 
phosphorylation of specific residues and differentially affects transcription and RNA processing 
(Hsin and Manley, 2012). Affinity chromatography allowed the identification of splicing factors 
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as CTD-binding proteins and phosphorylated CTD has been demonstrated to stimulate splicing 
in vitro through the association with the core of spliceosome (Hsin and Manley, 2012; David et 
al., 2011). These evidences added to the finding that CTD is more efficient in promoting splicing 
of a substrate with associated exon definition factors, raised the hypothesis that CTD might 
function as a platform to assist exon definition and commitment complex formation.  
1.3.3 Chromatin and histone modifications as regulators of alternative 
splicing  
RNA-binding elements, RNA polymerase II elongation rate and CTD cannot fully explain the 
regulation of alternative splicing. Recently, a role of chromatin structure and histone 
modifications have been pointed out (Luco et al., 2011). A first evidence on the involvement of 
chromatin structure in alternative splicing came from studies that highlighted the physical 
interaction between the histone acetyltransferase STAGA with U2 snRNP (Martinez et al., 2001) 
and the histone arginine methyltransferase CARM1 with U1 snRNP (Cheng et al., 2007), 
suggesting a role for chromatin complexes in facilitating the assembly of spliceosome to the 
nascent mRNA. Moreover, genome-wide mapping of nucleosome positioning showed that 
nucleosomes are non-random positioned along genes and are mainly enriched at intron-exon 
junctions, thus marking exons (Andersson et al., 2009). Interestingly, the average size of a 
mammalian exon equals the length of the DNA wrapped around a nucleosome, suggesting a 
protective role of nucleosome (Schwartz et al., 2009). Furthermore, included alternative exons 
are more enriched in nucleosome than excluded exons (Schwartz et al., 2009) and nucleosome 
density is higher in correspondence of weak splice sites (Spies et al., 2009). It has been also 
demonstrated that nucleosomes behave as a barrier that locally modulate RNA polymerase II 
elongation rate inducing its pausing, so that nucleosomes and RNA polymerase II may cooperate 
in the regulation of alternative splicing by favouring the recruitment of splicing factors (Hodges 
et al., 2009a).  
Histone modifications are emerging as important regulators of alternative splicing. Genome-wide 
analysis of histone modifications, revealed that they are non random distributed in the genome 
with some modifications specifically enriched in exons (Kolasinska-Zwirz et al., 2009). In 
particular, trimethylated H3K36 (H3K36me3), H3K4me3 and H3K27me2 are higher in 
alternatively spliced exons while H3K9me3 is depleted (Dhami et al., 2010; Spies et al., 2009). 
Moreover, the level of histone modifications does not correlate with the transcription activity of 
genes, supporting a role of histone modifications in alternative splicing (Andersson et al., 2009). 
Additional evidences come from treatment of cells with the histone deacetylase inhibitor 
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trichostatin A (TSA) that causes skipping of the alternative exon 33 of fibronectin and exon 18 
of the neural cell adhesion molecule (Nogués et al., 2002). Another clear example of histone 
modification-guarded alternative splicing is represented by the human fibroblast growth factor 
receptor 2 (FGFR2), whose exons IIIb and IIIc are mutually exclusive included in the mature 
mRNA depending on the cell specific type in which the receptor is expressed. In mesenchymal 
cells, H3K36me3 and H3K4me3 histone modifications are enriched in exon IIIc, that is 
preferentially included, while in epithelial cells the same histone modifications are enriched in 
exon IIIb, achieving by this way a tissue-specific isoform expression (Luco et al. 2010). Also 
DNA methylation has been proposed as a mechanism of alternative splicing regulation based on 
the non random presence of DNA methylation patterns across the genome and on the correlation 
between the methylation levels and H3K36me3 (Hodges et al., 2009b). 
Recently, a direct physical crosstalk between chromatin and splicing machinery has emerged 
from studies of genes whose alternative splicing is induced by the polypyrimidine-tract binding 
protein (PTB) splicing factor. Indeed, PTB-spliced genes are enriched in H3K36me3 and 
depleted in H3K4me3 at the level of alternatively spliced regions (Luco et al., 2010). The 
mechanism by which H3K36me3 influences alternative splicing is not imputable to the 
modulation of RNA polymerase II elongation rate, but to the formation of a chromatin platform 
that facilitates the recruitment of the splicing machinery to the nascent RNA via an adaptor 
protein, MRG15 (Luco et al., 2010). High levels of the H3K36me3 attract MRG15 that recruits 
PTB, in this way, to the nascent RNA that in turn causes the skipping of the alternative exon. If 
levels of H3K36me3 are low, PTB cannot be recruited to the pre-mRNA and thus the PTB-
dependent alternative exon is included in the mature mRNA (Luco et al., 2010). Similar 
mechanisms of action involve other chromatin-splicing adaptor systems. For example, the 
chromatin-adaptor protein CHD1 seems to play a role in the recruitment of the early spliceosome 
to the cyclin D1 pre-mRNA via H3K4me3 (Sims et al., 2007). Moreover, mass spectrometry 
analysis revealed that also HP1α/β acts as a chromatin-adaptor protein by interacting with 
H3K9me and recruiting SRp20 and ASF/SF2 alternative splicing factors (Loomis et al., 2009). 
1.3.4 ncRNA in alternative splicing 
Recently ncRNAs have been pointed out as novel modulators of alternative splicing. One of the 
proposed mechanisms involved the regulation of a key splicing factor by microRNA (miRNA) 
during development and differentiation. For example, the neuron-specific miR-124 directly 
regulates the expression of the splicing repressor PTB, triggering a neuronal-specific splicing 
program essential for differentiation of neural progenitor into mature neurons (Makeyev et al., 
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2007). In differentiating myoblasts, instead, upregulation of miR-133 leads to downregulation of 
nPTB and the activation of a muscle-specific differentiation program (Boutz et al., 2007). Apart 
from microRNA, other ncRNAs have been implicated in the regulation of alternative splicing. 
The long ncRNA MALAT-1 seems to control the pool of available SR proteins in the 
nucleoplasm, by binding and sequestering SR proteins in nuclear speckles (Tripathi et al., 2010). 
In addition to this indirect mechanism, a direct regulation of alternative splicing by ncRNAs has 
been suggested. The brain-specific small nucleolar RNA (snoRNA) HB-52II is processed in 
psnoRNAs, smaller variants that are reported to complementary bind to a silencer element in 
exon Vb of the serotonin receptor 5-HT2C pre-mRNA. By this way psnoRNAs mask the binding 
site for a splicing repressor thus favouring alternative exon inclusion (Kishore et al., 2010; 
Kishore and Stamm, 2006). 
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1.4 Alternative splicing and cancer  
The plasticity offered by alternative splicing to model the proteome according to specific cell 
requirements and developmental stages, makes alternative splicing a tempting target for cancer 
cells to enhance the production of protein isoforms sustaining tumour growth and spread. 
Subverted alternative splicing is commonly observed during tumour initiation and progression 
and accompanies the known and emerging hallmarks of cancer cells including reprogrammed 
metabolism, evasion of apoptosis, deregulated cell cycle control, chromosomal instability, 
invasion, metastasis and neoangiogenesis (Venables 2004; Ghigna et al., 2008, Hanahan and 
Weinberg, 2011). Two main alterations in differentially spliced isoforms in tumours have been 
identified: the expression of aberrant isoforms or the re-expression of protein isoforms usually 
thinly associated with distinct developmental stages and donwnregulated in differentiated cells 
(Figure 8). The first class of alterations are caused by mutations in oncogenes and 
oncosuppressors leading to aberrantly spliced isoforms that are advantageous to transformed 
cells and positively selected during tumour progression (Grosso et al., 2008). On the other hand, 
specific splice variants are reported to be commonly found enriched in cancer tissues where the 
spliced genes are not mutated, indicating that the defects imply alterations in the mechanism of 
splice site selection. It has been reported that these alterations mainly consist of cis-acting 
mutations of splice sites or splicing regulatory sequences or deleterious modifications in trans-
acting factors (Grosso et al., 2008).  
 
 
Figure 8. Alterations of splicing patterns commonly found in cancer (Srebrow and Kornblihtt, 2006). 
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1.4.1 Cis-acting mutations 
Inherited or somatic mutations affecting splicing process can be subdivided in two subclasses: i) 
class I, occurring in 60% of cases, includes splicing mutations at the canonical splice sites that 
completely abolish exon recognition; ii) class II mutations affect either the variable motifs 
(polypyrimidine tract and regulatory sequences) or are associated with the formation of cryptic 
donor or acceptor splice sites (Ghigna et al., 2008).  
 
Kruppel-like factor 6. KLF6 is a zinc finger transcription factor that acts as a tumour 
suppressor by inhibiting cell growth via activation of the cyclin-dependent kinase inhibitor p21. 
A single nucleotide polymorphism associated to prostate cancer creates a new binding site for 
the SR protein SRp40 leading to increased expression of the KLF6-SV1 isoform. This alternative 
isoform results from the use of an alternative 5’ splice site and encodes for a protein that lacks 
the zinc finger DNA-binding domain but retains the activation domain (DiFeo et al., 2009; Narla 
et al., 2005a). KLF6-SV1 acts as a dominant-negative protein and antagonises the activity of the 
canonical KLF6, favouring cell proliferation and migration (Narla et al., 2005b).  
 
Cyclin-dependent kinase inhibitor 2A. The CDKN2A gene encodes two tumour suppressors, 
p14
ARF
 and p16
INK4a 
that control the G1/S transition via the Rb and p53 proteins, respectively. 
Loss of function of these two proteins has been associated to melanoma development (Nelson 
and Tsao, 2009). A new mutation in the acceptor splice site of intron 1, that promotes skipping 
of exon 2 in both p14
ARF
 and p16
INK4a
 and consequent protein inactivation, has been found in a 
family with melanomas, neurofibromas and multiple dysplatic naevi (Petronzelli et al., 2001).  
 
Liver kinase B1. LKB1 is a tumour suppressor gene that encodes for a Ser-Thr kinase involved 
in different cellular processes (cell cycle arrest, p53-mediated apoptosis, cell polarity etc.). 
Mutations in LKB1 are associated to the Peutz-Jeghers Syndrome (PJS, OMIM #175200), an 
autosomal dominant disorder characterised by gastrointestinal polyposis and increased cancer 
risk. A fraction of PSJ patients carries a mutation at the 5’ splice site of intron 2. The mutated 
splice site is still used but in conjunction with a cryptic 3’ splice site close to the canonical one, 
leading to frameshift and premature termination codon in the aberrantly spliced isoform 
(Hastings et al., 2005). 
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Receptor tyrosine kinase KIT. C-kit is aproto-oncogene constitutively activated in multiple 
cancers and found to be activated by aberrant splicing in some cases of gastrointestinal stromal 
tumours (GISTs). Patients carrying a deletion of the intron-exon segment that harbours the 3’ 
splice site of intron 10 show a constitutively active aberrant protein isoform produced by a new 
exonic 3’ splice site created within exon 11 (Chen et al., 2005).  
 
Liver intestine cadherin. CDH17 is a cell-cell adhesion protein overexpressed in hepatocellular 
carcinomas, gastric and pancreatic cancers. Splice variants with skipping of exon 7 have been 
associated with poor prognosis and a high incidence of tumour recurrence. Skipping of exon 7 is 
mainly caused by a point mutation that disrupts the branch site in intron 6 and a second point 
mutation at position 651 in exon 6 which might either generate an ESS or disrupt an ESE (Wang 
et al., 2005). 
 
Breast cancer type 1 susceptibility protein. BRCA1 is a well-known breast and ovarian cancer 
predisposing gene. The first splicing mutation identified in this gene was a nonsense mutation in 
exon 18 that actually disrupts an ESE leading to skipping of exon 18 (Mazoyer et al., 1998). 
Since the identification of this splicing mutation, a multitude of mutations affecting BRCA1 
splicing have been reported and in silico analysis of splicing regulatory sequences in BRCA1 
revealed that at least 60% of these sequences are target of mutation (Pettigrew et al., 2005). 
1.4.2 Alteration in trans-acting factors 
Most cancer-associated aberrant splicing are not associated to mutations in the affected gene, 
suggesting alterations in the expression and/or activity of splicing regulatory factors (Vénables 
2004). Indeed, alterations in the repertoire of SR and hnRNP proteins are frequently observed in 
cancer accompanied by alterations in the relative expression of splicing isoforms, which 
represent an hallmark of cancer cells (Ladomery, 2013). Therefore, specific alternative spliced 
isoforms are favoured in tumours and appear fundamental to sustain the transformation process 
(Singh et al., 2004; Zhou et al., 2003).  
 
CD44. The trans-membrane glycoprotein CD44 has been one of the first genes for which 
changes in alternative splicing were demonstrated to be associated with alterations in growth 
signalling pathways. CD44 is involved in cell-cell and cell-matrix interactions and different 
isoforms are produced by inclusion of 10 alternative exons (v1-v10) belonging to its extra-
cellular domain (Naor et al., 2002). The CD44 isoform lacking all the alternative exons, is 
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predominantly expressed in normal tissues, while alternative isoforms, in particular those 
containing v5, v6 and v7, are overexpressed in tumours where they promote cell invasion and 
metastasis (Naoret al., 2002). In tumours it has been demonstrated a direct correlation between 
expression levels of the alternative CD44 isoforms, overexpression of SR proteins and alterations 
in the expression of other splicing factors, among which hnRNPA1, SRp55, SF2/ASF, Tra-2-
beta, YB-1 and Sam68 (Ghigna et al., 1998; Stickeleret al., 1999; Watermann et al., 2006). In 
particular, Matter and colleagues demonstrated that, in cancer cells, Sam68 (Src-associated in 
mitosis 68-kDa) favours v5 inclusion as a consequence of activation of the Ras-Raf-Mek-Erk 
pathway (Matter et al., 2002). They suggested that phosphorylated Sam68 binds exon v5 and 
blocks the repressive activity of hnRNP A1, confirming the direct connection between a 
mitogenic signalling pathway and alternative splicing. Afterwards, Cheng and Sharp proved that 
also SRm160 is another Ras-regulated splicing factor involved in CD44 exon v5 inclusion and 
correlated this tumour-specific alternative splicing to invasiveness and metastasis (Cheng and 
Sharp 2006).  
 
Fibronectin. Fibronectin is an extracellular matrix component that has been associated to 
proliferation, migration, invasion and metastasis in tumours. Indeed, the fibronectin alternative 
isoform EDA, produced by the inclusion of an additional exon, is expressed at low levels in 
normal adult tissues, but is detectable in embryos, during wound healing process and in tumours. 
Growth factors appear to induce EDA exon inclusion through activation of the Ras/PI3-
kinase/AKT pathway. Direct phosphorylation of the SR proteins 9G8 and SF2/ASF by AKT 
promote the recognition of EDA exon by the spliceosome (Blaustein et al., 2005).  
 
Bcl-X. Bcl-X is a member of the Bcl-2 family and is involved in apoptosis. Two alternative 
isoforms are produced through the use of alternative 5’ splice sites in exon 2: Bcl-XL, with pro-
apoptotic function and the antiapoptotic Bcl-XS (Akgul et al., 2004). Different splicing factors 
have been associated to the Bcl-X alternative splicing. Overexpressed Sam68, in particular, has 
been demonstrated to induce the production of Bcl-XS. The 5’ splice site choice appears to be 
driven by the lipid ceramide pathway (Massiello and Chalfant, 2006). Ceramide is also able to 
modulate the phosphorylation status of SR proteins, among which SF2/ASF, one of the major 
regulators of Bcl-X alternative splicing (Massiello et al., 2006). The ratio between Bcl-XL and 
Bcl-XS is critical to determine the sensitivity of cells to apoptotic signals and alteration of this 
balance in cancer cells promotes cell survival, drug and chemotherapy resistance (Paronetto et 
al., 2007).  
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Ron. The “Recepteur d’origine nantais” (Ron) is a tyrosine kinase receptor for the macrophage 
stimulating protein (MSP). MSP binding results in tyrosine autophosphorylation of the receptor 
and, consequently, in the activation of several pathways involved in motility and extracellular 
matrix invasion (Ghigna et al., 2005; Wagh et al., 2008). Ron alternative splicing is frequently 
altered in tumours. Till today about six Ron splice variants, called ΔRon, have been reported. All 
these variants are characterised by deletions that make the receptor constitutively active (Lu et 
al., 2007). In particular, the ΔRon165 originates from skipping of exon 11, leading to a 49 
aminoacids in frame deletion in the extracellular domain (Ghigna et al., 2005). This isoform is 
expressed in breast and colon cancers, as a result of overexpression of the SR protein SF2/ASF, 
which binds to an ESE in exon 12 and induces exon 11 skipping. The expression of ΔRon165 
leads to the morphological and functional changes characteristic of the epithelial-to-
mesenchymal transition in cancer cells (Ghigna et al., 2005). 
 
Rac1. Rac1 is a GTPase that has a fundamental role in cell migration, cell proliferation and in 
the production of reactive oxygen species (Bosco et al., 2009; Kheradmand et al., 1998). 
Mutations of Rac proteins are very rare in cancer, but alterations in Rac alternative splicing have 
been detected in colorectal and breast cancers leading to the production of a Rac1 isoform, called 
Rac1b, which contains an additional exon of 57 nucleotides (Jordan et al., 1999). Racb1b 
mediates matrix metalloproteinase-3 (MMP3)-induced malignant transformation (Radisky et al., 
2005). By transient overexpression of different splicing regulators Jordan and colleagues found 
that SRF1 increases Rac1b expression, while SRp20 and 9G8 have the opposite effect. They also 
demonstrated that inhibition of the Wnt/β-catenin pathway reduces SRF3 levels and increases 
Rac1b expression (Goncalves et al., 2009).  
 
VEGFA. Vascular endothelial growth factor A is the most important ligand secreted by tumour 
cells to promote the formation of new vessels in hypoxia conditions. VEGFA mRNA undergoes 
alternative splicing and the most abundantly expressed isoform in adult tissues is VEGF165b, 
resulting from the use of a 3’ alternative splice site in the last exon. The expression of the 
canonical VEGF transcript is upregulated in several tumours associated with reduced levels of 
VEGF165b (Woolard et al., 2004). VEGF165b acts as an inhibitor of angiogenesis, binding to 
VEGFR but failing to engage the multimeric complex required for the full activation of VEGFR 
(Kawamura et al., 2008). In tumours, overexpression of SRPK1/2, SRSF1 and SRSF5 SR 
proteins has been associated with canonical VEGFA increased expression (Nowak et al., 2008). 
 
Introduction 
 
 
 
25 
Cyclin D1. Cyclin D1 is a master regulator of cell cycle by binding to cyclin-dependent kinase 4 
or 6. Alternative splicing of Cyclin D1 produces two isoforms: Cyclin D1a, the full-length 
variant with five exons, and Cyclin D1b which is polyadenylated within intron 4 (Betticher et al., 
1995). Even if Cyclin D1b can be detected in non cancerous tissues, it is upregulated in tumour 
cells, including prostate and breast carcinomas (Burd et al., 2006; Wang et al., 2008). At 
difference of the D1a isoform, D1b is constitutively localised in the nucleus and by this way it 
escapes degradation (Lu et al., 2003). The choice between D1a and D1b expression is driven by 
a competition between splicing and polyadenylation of intron 4. It has been reported that a 
common polymorphism in the last nucleotide of exon 4, G870A, affects the exon recognition by 
the splicing machinery and results in polyadenylation of intron 4 and thus in the expression of 
the D1b isoform. Interestingly, the G870A polymorphism, is associated with an increased risk to 
develop multiple cancers (Knudsen et al., 2006). In addition, in cancer cells, the expression of 
D1b is also stimulated by overexpressed Sam68 and SRF1 splicing proteins (Paronetto et al., 
2010; Olshavsky et al., 2010).  
1.4.3 Splicing as a target of therapy  
As discussed above, alterations in alternative splicing determine a splicing signature that appears 
specific and instrumental for each cancer cell type. The presence of cancer-specific isoforms that 
are expressed as a consequence of mutations, or the altered ratio of physiologically expressed 
isoforms as a result of splicing factors alterations, make the alternative splicing a promising field 
to identify diagnostic and prognostic markers and for design of new therapeutic strategies. One 
of the mechanism exploited for targeting cancer-associated splice variants involves the use of 
antibodies conjugated with radioisotopes (Figure 9A). 
 
 
Figure 9. Therapeutic approaches to target alternative splicing in cancer cells (Ghigna et al., 2008). 
A B
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These antibody-based tumour target strategies are particularly useful for surface receptors 
involved in cell-cell and cell-matrix interactions that are frequently spliced in a tumour specific 
manner. For example, radiolabelled antibodies raised against CD44-v6 are promising therapeutic 
tools and are now in clinical trials for head and neck cancer treatment (Börjesson et al., 2003).  
Small molecules have also been tested to modify alternative splicing patterns in cancer (Figure 
9B). Since phosphorylation of SR proteins is the best characterised post-translational 
modification of splicing factors, small molecule kinase inhibitors have been designed against 
GSK3, one of the most important kinases involve in the activation of SR proteins. Even if these 
innovative drugs appear to be efficient in restoring alternative splicing events driven by GSK3, a 
major challenge in their application is represented by the involvement of the target in several 
pathways, making this therapeutic strategy not very specific (Hernandez et al., 2004). Short 
antisense oligonucleotides (AONs), complementary to a portion of the target mRNA are in study 
to reverse or correct aberrant splicing (Figure 9C). The synthetically modified oligonucleotides 
block the inappropriate exon selection by binding to splice sites or splicing regulatory sequences 
and have proven efficient in correcting the alternative splicing of the dystrophin gene, in both 
Duchenne and Becker muscular dystrophies, β-globin, CFTR and tau genes (Sazani and Kole 
2003). Finally, small interfering RNAs (siRNAs) have been used to downregulate the expression 
of SR and/or hnRNP proteins in cancer (Figure 9C). They appear to be effective in inducing 
apoptosis and increasing chemotherapy sensitivity of cancer cells by downregulation of SRPK1 
expression and hence affecting the expression of Bcl2 and Bax proteins (Hayes et al., 2006).  
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1.5 Alternative splicing in brain 
Alternative splicing is particularly exploited in the central nervous system (CNS), where it 
represents a key mechanism for the fine tuning of protein isoform expression needed for CNS 
proper development and function maintenance. In the CNS thousands of alternatively spliced 
isoforms are produced and translated into related protein isoforms that take part in several 
processes including learning and memory, neuronal cell recognition, neurotransmission, ion 
channel function, and receptor specificity (Grabowski and Black, 2001). Most mRNA have been 
demonstrated to undergo different splicing during neuronal development or be alternatively 
spliced in different brain regions to achieve a high specificity of functions.  
Several nervous system diseases are associated with abnormalities in alternative splicing leading 
to alterations in the abundance, location or timing of isoform expression.  
 
1.5.1 Brain-specific regulation of alternative splicing 
Representative examples of CNS-specific alternative splicing concern the genes encoding for 
GABAA, tyrosine kinases (c-src) and tropomyosin. A common feature of these splicing events is 
the involvement of the polypyrimidine-tract binding protein (PTB), which is a member of the 
hnRNP family (Dreyfuss et al., 1993).  
As regards splicing enhancement, as previously described (see 1.2.1) it is mainly accomplished 
by SR proteins binding to ESE or ISE sequences. In the CNS tissue specificity is achieved also 
by targeted expression of SR proteins or regulatory factors. For example, the SR-specific kinase 
2 (SRPK2) is mainly expressed in brain where it is believed to fulfil tissue and developmental-
specific alternative splicing events (Wang et al., 1998). It has been reported that the ratio of SR 
proteins plays a significant role in the regulation of alternative splicing in brain (Hannamura et 
al., 1998). Generally, this mechanism involves the ratio of splicing proteins with opposing 
activities, like ASF/SF2 which expression is inversely proportional to the expression of hnRNP 
A1. 
CELF (CUG binding proteins and ETR3 like factors) proteins have been identified as a new 
class of brain-specific alternative splicing regulators. CELF proteins are expressed with a 
varying tissue specificity and regulate alternative splicing of CLCB and NMDA favouring 
inclusion of cassette exons (Zhang et al., 1999).  
Different neuron-specific RNA binding proteins have been identified and associated with defined 
splicing patterns in the CNS. The elav protein family, firstly identified in Drosophila 
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melanogaster, comprises different members, exclusively expressed in neurons, that participates 
in the regulation of mRNA stability and metabolism during neural development (Antic et al., 
1999; Atasoy et al., 1998). Moreover, the expression of Nova-1 and Nova-2 is restricted to the 
nucleus of neurons where these two splicing repressors are involved in the regulation of GlyRα2 
and GABAA receptors (Jensen et al., 2000).  
 
1.5.2 Alterations of alternative splicing in brain diseases  
 
Neurodegeneration. Mutations in the tau gene represent a clear example of the effects of 
mutations in alternative splicing. Tau belongs to the MAP (Microtuble Associated Protein) 
protein family and is involved in microtubule assembly and stabilisation upon phosphorylation 
by specific kinases, including MARK4 (MAP/Microtubule Affinity Regulating Kinase 4) 
(Cleveland et al., 1977). At least six different tau isoforms are produced by alternative splicing, 
and most of them differ in the numbers of microtubule (MT)-binding motifs. In particular, exon 
10 exclusion/inclusion determines the formation of tau proteins with three (Tau3R) or four 
(Tau4R) MT-binding motifs, respectively. In normal human brain the ratio of Tau4R/Tau3R is 
approximately 1 (Goedert et al., 1998; Hong et al., 1998; Hutton et al., 1998). 
Mutations in the tau gene cause the frontotemporal dementia with parkinsonism linked to 
chromosome 17 (FTDP-17), characterised by filamentous aggregates of tau protein in neurons 
and glial cells, a feature also reported in Alzheimer’s disease. Several mutations in FTDP-17 
patients are associated with increase in the ratio of Tau4R/Tau3R, suggesting that the proper 
ratio between the two isoforms is essential for neuronal survival and functions (Spillantini and 
Goedert, 1998). These splicing mutations include both intronic and exonic mutations. Many 
intronic mutations in FTDP-17 patients are near to the 5’ splice site of intron 11 and result in 
destabilisation of the stem and loop RNA structure leading to increased interaction of U1 snRNP 
with the 5’ splice site, enhanced exon 10 inclusion and hence increase in the Tau4R/Tau3R ratio 
(Jiang et al., 2003). Also mutations in exon 10 have been found to affect tau splicing. Indeed, 
Jiang and colleagues demonstrated the presence of an exonic splicing enhancer (ESE) in exon 10 
whose mutations enhance the binding of the splicing regulator Tra2β and thus exon 10 inclusion 
(Jiang et al., 2003). Further studies also revealed that Tra2β works in competition with another 
SR protein, SRp54, that, in this case, antagonises exon 10 inclusion (Wu et al., 2006). 
Studies on spinal muscular atrophy have highlighted that this motor neurons degenerative 
disease can be considered a trans-acting splicing disorder. Indeed, the survival motor neurons 
(SMN) gene is required for regeneration and recycling of spliceosomal snRNPs (Pellizzoni et al., 
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1998). Therefore, it has been proposed that mutations in the SMN gene reduce the functional 
protein, impairing pre-mRNA splicing.  
 
Neurological and psychiatric disorders. Mutations in both cis-acting and trans-actin splicing 
factors have been associated with neurological diseases. A representative example isprovided by 
a nonsense mutation in the dystrophin gene leading to exon 31 skipping by activation of an 
exonic splicing silencer for the hnRNP A1 protein (Disset et al., 2006). Mouse models of type 2 
myotonic dystrophy (DM), caused by CCUG expansion in intron 1 of the zinc finger protein 9 
(ZNF9) gene (Ranum and Day, 2004), have revealed that actually repeats expansion results in 
the sequestration and upregulation of MBNL and CUG-BP1 splicing factors, leading to 
misregulation of alternative splicing in striated muscle and brain of DM patients (Kanadia et al., 
2006; Ranum and Cooper, 2006).  
Schizophrenia, one of the major psychiatric disorders, is reported to have a causative component 
inaberrant alternative splicing too. In particular, increase in the γ2L versus the γ2S isoform of 
GABAA receptor has been reported in schizophrenic patients with detrimental effects on cortical 
functions (Huntsman et al., 1998). Alterations in the relative abundance in specific isoforms of 
the neural cell adhesion molecule (VASE) and the NMDR1 receptor have been pointed out and 
correlated with compromised neuronal functionality in schizophrenia patients (Vawter et al., 
2000; Le Corre et al., 2000).  
 
Glioma. Gliomas are the most common primary brain tumours in adults, accounting for about 
70% of all the tumours in the CNS (Ohgaki 2009). According to the updated World Health 
Organization (WHO) classification (Rousseau et al., 2008), gliomas can be histologically sub-
divided in astrocytic tumours, including astrocytoma and glioblastoma, oligodendroglial 
tumours, mixed gliomas, ependymomas and other neuronal, neuro-glial and neuroepithelial 
tumours. Gliomas are also classified in four malignancy grades (WHO grade I-IV) according to 
the presence/absence of nuclear atypia, mitosis, microvascular proliferation and necrosis. Brain 
tumour stem cells are thought to be responsible for glioma growth, invasiveness and resistance to 
chemotherapy and radiation (Reya et al., 2001). Different hypotheses have been formulated on 
the brain tumour stem cell origin which may derive from de-differentiation of mature glial cells, 
neural progenitors or neural stem cells (Vescovi et al., 2006; Canoll et al., 2008; Germano et al., 
2010).  
Most brain tumours are sporadic, even if a few familiar syndromes are associated with an 
increased incidence of brain neoplasia. Alternative splicing can be included among the processes 
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targeted by oncogenic alterations in glioma. Different splicing factors have been reported to 
drive an oncogenic splicing switch in glioma. Among them hnRNP H, which is upregulated in 
glioma, favours the aberrant expression of the anti-apoptotic isoform MADD of the insuloma 
glucagoma protein 20 (IG20/MADD) and the constitutively active RON isoform in glioma 
(LeFave et al., 2011). Moreover, hnRNP A2/B1 are considered putative proto-oncogenes in 
glioma, since their overexpression is sufficient to induce malignant transformation in vitro 
probably through aberrant RON splicing (Golan-Gerstl et al., 2011).  
Alternative splicing of FGFR1 (Fibroblast Growth Factor Receptor 1) is also impaired in glioma. 
Increased skipping of α exon leads to the overexpression of a high affinity isoform that confers a 
growth advantage to glioma cells. Several intronic splicing repressors have been characterised in 
introns flanking α exon and are thought to be involved in aberrant FGFR1 splicing (Wang et al., 
1995). 
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1.6 Polypyrimidine-tract binding protein (PTB) 
Polypyrimidine-tract binding protein (PTB) is an ubiquitous splicing regulator belonging to the 
hnRNP protein family. It was originally identified for its ability to induce exon skipping, but it is 
currently shown to play a role in different cellular processes including polyadenylation, mRNA 
stability and translational initiation. PTB has aroused particular interest for its involvement in 
neural development and glioma.  
 
1.6.1 PTB transcription, alternative splicing and protein structure 
The PTB gene is localised on chromosome 19p13.3 and it is expressed in four differently spliced 
isoforms. PTB, also known as PTBP1, derives from an mRNA that undergoes skipping of exon 9 
(mRNA 3203 base pairs; 531 aminoacid protein). PTBP2 (mRNA 3260 base pairs ; 550 
aminoacid protein) and PTBP4 (mRNA 3281 base pairs; 557 aminoacid protein) result from 
exon 9 inclusion and the use of two alternative 3' splice sites, while PTB-T has been reported to 
result from alternative splicing of exons 2-10 (Sawicka et al., 2008).  
PTB encodes for a 57 kDa protein characterised by four RNA recognition motifs (RRMs) and a 
conserved N-terminal domain that harbors both nuclear localisation and export signals (NLS and 
NES). Through the RRMs, PTB binds to the transcript at multiple sites within large 
polypyrimidine tracts leading to conformational changes suitable to functional mRNA 
processing (Sawicka et al., 2008). PTB shuttles continuously between the nucleus and the 
cytoplasm. Cytoplasmic localisation is mainly induced by the PKA-mediated phosphorylation of 
a specific serine residue(Ser-16) within the NLS and predominantly occurs during cell stress 
(Sawicka et al., 2008). PTB has also been considered a key component in maintaining the 
integrity of the perinucleolar compartment, a subnuclear structure predominantly found in 
transformed cells (Wang et al., 2003). 
 
1.6.2 PTB expression and neuronal differentiation 
PTB is ubiquitously expressed, but it is reported to play a major role in guiding alternative 
splicing in brain. Indeed, a splicing switch from PTB to its highly homolog neuronal PTB 
(nPTB) drives neuronal differentiation. The expression of PTB and nPTB is mutually exclusive, 
with PTB expressed in neural precursors and glial cells, while post-mitotic neurons express only 
nPTB (Boutz et al., 2007). PTB expression is regulated by PTB itself through alternative 
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splicing. In particular, PTB binds to its mRNA and induces the skipping of exon 11 and the 
consequent degradation of the resultant frameshift mRNA through non-sense mediated mRNA 
decay (Wollerton et al., 2004). A regulatory expression loop, that exploits alternative splicing, 
also is acting between PTB and nPTB (Spellman et al., 2007). By this mechanism PTB 
downregulation in neuronal-committed neural progenitors is sufficient to induce nPTB 
expression and changes in the alternative splicing program lead to neuronal differentiation 
(Boutz et al., 2007). nPTB is highly homologous to PTB and the two proteins are very similar in 
the structure of their RRMs. They bind to the same regulatory elements but with some 
differences in affinity (Markovtsov et al. 2000; Oberstrass et al. 2005). Moreover, as previously 
reported (see 1.3.4), mir-124 regulates the expression of PTB in non-neuronal cells (Makeyev et 
al., 2007). Xue and colleagues recently demonstrated that downregulation of PTB is able to 
induce trans-differentiation of fibroblasts into neuronal-like or even functional neurons in vitro. 
In this context, PTB appears to be a fundamental component of a microRNA program that 
dismantles multiple components of the REST complex (RE1-silencing transctiption factor) (Xue 
et al., 2013). This transcriptional complex downregulates the expression of a large array of 
neuronal specific genes in non-neuronal cells, including mir-124, thus priming an autoregulatory 
loop during neuronal differentiation. Thus, PTB is not only a target of mir-124, but also 
negatively regulates the expression of this and other miRNA important for neuronal 
differentiation and induces the expression of critical transcription factors needed to promote 
trans-differentiation of mouse embryonic fibroblasts (MEFs) into functional neurons (Xue et al. 
2013). 
Other insights into the function of PTB in neural development come from studies on mouse 
embryonic stem cell lines (ES). Shibayama and colleagues demonstrated that PTB homozygous 
mutations cause embryonic lethality shortly after implantation, while Ptb
-/- 
ES show severe 
defects in cell proliferation, apparently without aberrant differentiation. Further analysis of cell 
cycle progression and cell synchronisation revealed that Ptb
-/- 
ES are characterised by prolonged 
G2/M phase, demonstrating that PTB is essential for early mouse development and ES cell 
proliferation (Shibayama et al., 2009). In 2011 Suckale and colleagues demonstrated that PTB is 
expressed in mouse developing organs, in particular in the brain cortex and sub-ventricular zone, 
well known regions of neurogenesis in both humans and mouse. In contrast with previous studies 
of Shibayama, they also found that ES lacking PTB not only show impaired proliferation, but 
also defective differentiation (Suckale et al., 2011). 
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1.6.3 PTB functions 
PTB was originally identified as repressor of alternative splicing (Garcia-Blanco et al., 1989) but 
Additional roles in mRNA processing, viraltranslation and replicationand IRES-mediated 
translation have been described(Sawicka et al., 2008). 
 
Regulation of alternative splicing. PTB commonly acts as repressor of alternative splicing 
favouring skipping of alternative exons. Different models of PTB activity have been proposed 
(Spellman and Smith, 2006) (Figure 10): i) binding competition with the splicing factor U2AF65 
at the 3' splice site of alternative exons; ii) polymerisation of PTB on the alternative exon 
masking splicing enhancer sequences; and iii) looping out of alternative exons by PTB binding 
of flanking intronic sequences.  
 
 
Figure 10. Mechanisms of PTB-derived alternative splicing. A) Competition with U2AF
65
 factor. B) Propagation: 
PTB polymerises along the pre-mRNA and masks binding sites for positive regulators of alternative splicing. C) 
Looping: PTB binds to both flanking introns and induces exon excision by looping it (adapted from Spellman and 
Smith, 2006). 
 
α-tropomiosin, α-actinin, GABAAγ2 (gamma aminobutyric acid Aγ2), c-src and FGFR2 
(fibroblast growth factor receptor 2) are known targets of PTB-mediated alternative splicing 
(Spellman et al., 2005). However, recent studies also reported a role of PTB in exon inclusion 
depending on the position of its binding sites relative to the target exon. In detail, upon binding 
to the upstream intron and/or within the exon, PTB represses exon inclusion, while by binding to 
the downstream intron, it activates exon inclusion, delineating a position-dependent activity. 
Specific splice site features determine the PTB-mediated repression or inclusion of alternative 
exons: included exons show weaker 5' splice sites, whereas skipped exons have longer 
polypyrimidine tracts (Llorian et al., 2010). 
A
B
C
= polypyrimidinetract
= branch point
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3'-end processing. PTB both promotes and inhibits the mRNA 3'-end cleavage required for 
polyadenylation. PTB may prevent mRNA polyadenylation through competition with the 
cleavage stimulating factor (CstF), or stimulate polyadenylation by binding to pyrimidine-rich 
upstream elements(USEs) (Castelo-Branco et al., 2004; Le Sommer et al., 2005). PTB is also 
involved in alternative polyadenylation, leading to mRNA with variable 3’ ends and thus 
proteins with different C-terminals. In this case PTB has been reported to bind to the same 
regulatory sequence identified for splicing repression but nearby alternative polyadenylation 
sites (Hall-Pogar et al., 2007).  
 
mRNA transport. Evidences for a role of PTB in mRNA transport come from experiments in 
Xenopus, where the PTB homologue (VgRBP60) is involved in the localisation of the Vg1 
mRNA (Cote et al., 1999). In vertebrates PKA-activated PTB is involved in α-actin mRNA 
localisation at neurite terminals, a fundamental process for cell motility and neuronal axon 
growth (Ma et al., 2007). PTB has also been reported to regulate the nuclear export of hepatitis B 
virus RNAs (Zang et al., 2001).  
 
mRNA stability. PTB increases the stability of specific transcripts by binding to the untranslated 
regions of mRNA and thus competing with factors involved in mRNA degradation. Glucose-
stimulated binding of PTB to the 3’-UTR of rat insulin mRNA has been demonstrated to increase 
mRNA stability by involving the mTOR pathway (Tillmar et al., 2002a). Also hypoxia may 
induces PTB binding to insulin mRNA, but without involvement of the mTOR pathway (Tillmar 
et al., 2002b). PTB, in association with CSD (cold shock domain) Y-box proteins, also controls 
the stability of VEGF (vascular endothelial growth factor) mRNA. CSD-PTB complexes bind to 
3’- and 5’-UTRs and lead to conformational changes that protect mRNA from degradation 
(Coles et al., 2004). Other mRNAs stabilised by PTB-binding include CD154 and iNOS 
(Hamilton et al., 2003; Pautz et al., 2006).  
 
Viral translation and replication. PTB acts as an ITAF (IRES -internal ribosomal entry site- 
trans-acting factor) for mRNA translation of virus belonging to the Picornaviridae family and 
lacking cap structure. Indeed, PTB binds to IRES elements containing large polypyrimidine 
tracts with PTB consensus binding sequences and stabilises or alters the IRES structure to direct 
ribosome binding to the correct start codon, thus acting as a chaperone (Song et al., 2005). 
Interestingly, PTB also binds to the HCV mRNA within IRES elements but it is not essential for 
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IRES activity, even if it stimulates viral replication (Chang and Luo, 2006). These evidences 
suggest that PTB might be a potential target for anti-HCV therapeutic agents (Xue et al., 2007). 
 
IRES-mediated translation. PTB has been also proposed as a general ITAF that allows IRES-
mediated translation under conditions that inhibit cap-dependent translation, such as cell stress, 
apoptosis and viral infection (Mitchell et al., 2005). Targets of PTB-induced IRES translation 
include BAG-1 (Bcl-2-associated athanogene 1) and Apaf-1 (apoptotic protease activating factor 
1) (Pickering et al., 2004; Mitchell et al., 2001). Cytoplasmic relocalisation of PTB is a critical 
factor in IRES-mediated translation. This relocalisation has been observed after exposure to 
chemotoxic agents and appears fundamental in IRES activation during apoptosis (Dobbyn et al., 
2008; Bushell et al., 2006).  
 
1.6.4 PTB and human pathologies  
Since PTB expression is thinly regulated in tissues, above all in brain, deregulation of its 
expression has been implicated in different pathologies, including glioma, ovarian cancer and 
Alzheimer’s disease.  
 
Glioma. PTB is aberrantly overexpressed in glioma and its expression levels correlate with glial 
cell transformation. Increased PTB expression contributes to gliomagenesis by deregulating the 
alternative splicing of genes involved in cell proliferation and migration, including FGFR-1 
(fibroblast growth factor receptor-1), PKM (pyruvate kinase) and USP5 (ubiquitin specific 
peptidase 5) (McCutcheon et al., 2004; Cheung et al., 2006). In particular, PTB overexpression 
increases FGFR-1 α-exon skipping that results in the synthesis of a receptor with higher affinity 
for the fibroblast growth factor thus favouring transformed cell growth (Jin et al., 2000).  
In transformed glial cells, PTB overexpression leads to the re-expression of the embryonic 
pyruvate kinase isoform, PKM2. The switch from PKM1, normally expressed in terminally 
differentiated cells, to PKM2 is achieved through the PTB-mediated inclusion in the PKM 
mRNA of exon 10, instead of exon 9. In transformed cells, PKM2 promotes aerobic glycolysis 
and proliferation. Recently c-Myc overexpression has been associated to upregulation of PTB 
transcription in transformed glialcells (David et al., 2010). 
In glioblastoma, PTB overexpression forces the expression of USP5 isoform 2, a protein 
involved in ubiquitination. USP5 isoform 2 has a low activity and favours cell growth and 
migration (Izaguirre et al., 2011). 
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Ovarian tumour. PTB is overexpressed in the majority of epithelial ovarian tumours and 
deregulates cell proliferation, anchorage-dependent growth and invasiveness. PTB targets in 
ovarian transformed cells have not yet been identified (He et al., 2007). 
 
 
Alzheimer’s disease (AD). Recent evidences delineate PTB as a regulator of the amyloid 
precursor protein (APP) expression in neurons. In particular, PTB altered expression in neuronal 
cells, likely mediated by miR-124, enhances the expression of APP isoforms including exon 7 
and/or 8. These isoforms have been found enriched in AD patients and associated with β-
amyloid production (Smith et al.,2011). 
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1.7 MAP/Microtubule Affinity Regulating Kinase 4 (MARK4) 
1.7.1 MARK4 gene, alternative splicing and protein structure 
MARK4 belongs to the MARK protein family (MARK1-4) and is the less characterised member 
of the family. The MARK4 gene was discovered by Kato and colleagues in 2001 and named 
MARKL1 (MARK-Like 1) on the basis of its homology to MARK (Kato et al., 2001).  
MARK4 gene maps on chromosome 19q13.2 and consists of 18 exons. Two different isoforms 
are produced through alternative splicing (Figure 11): MARK4S (short), the constitutive isoform 
consisting of 18 exons (3609 base pairs), with the stop codon included in the last exon, and 
encoding a 688 aminoacid long protein; and MARK4L (long) a 752 aminoacid protein translated 
by a transcript that undergoes skipping of exon 16 and the consequent frameshift of the reading 
frame. 
 
 
 
Figure 11. MARK4 alternative splicing. 
 
 
MARK4 sequence shares near 55% homology with the other MARKs, with the highest 
homology with MARK3. MARK4 isoforms show the characteristic MARK protein structure and 
domains, including an N-terminal catalytic domain, a linker domain (common docking domain), 
an ubiquitin associated (UBA) domain, a spacer domain and a C-terminal tail. The functional 
kinase domain shares 90% homology with the other MARKs. The MARK4 characteristic T-loop 
harbours the activating (T214) and the inhibitory (S218) phosphorylation sites. MARK4 
alternative splicing leads to the production of two protein isoforms that differ in the C-terminal 
tail: MARK4L shows the Kinase-Associated 1 (KA1) domain, like the other MARK proteins, 
whereas MARK4S contains a domain with no homology with any known structure (Espinosa et 
al., 1998), suggesting non-overlapping functions of the two isoforms. Despite the MARK4 tail 
MARK4LmRNA
5’ 3’15 16 17 18
MARK4S mRNA
5’ 3’15 16 17 18
stop stop
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domain shows low sequence homology compared to the other MARKs it folds in a conformation 
similar to those of MARK1, 2 and 3, thus suggesting an autoinhibitory and interactor binding 
function also for the MARK4 C-terminal region (Marx et al., 2010). 
 
1.7.2 MARK4 regulation 
Given the conserved protein structure compared with the other MARK proteins, the regulation of 
MARK4 protein function has been inferred from the other family members.  
MARK4 is activated by LKB1 (Liver Kinase B1) that phosphorylates the threonine 214 residue 
inside the T-loop (Lizcano et al., 2004; Brajenovic at al., 2004). It has been recently 
demonstrated that MARK4 is polyubiquitinated and interacts with USP9X, a deubiquitinating 
enzyme. MARK4 mutants in USPX9 binding sequence are hyperubiquitinated and not 
phosphorylated at the T214, thus inhibiting LKB1 activation. Ubiquitin binds the MARK4 UBA 
domain in the steady state making the T-loop not accessible to LKB1. An alternative model 
predicts that ubiquitin may mask the T214 site or induce conformational modifications favouring 
the action of phosphatases (Al-Hakim et al., 2008). MARK4 has also been demonstrated to 
interact with aPKC (Brajenovicet al., 2004) and thus it may be phosphorylated and inactivated 
by this kinase, as reported for MARK2 and MARK3 (Hurov et al., 2004). 
 
1.7.3 MARK4 interactors 
Tandem Affinity Purification (TAP) and immunoprecipitation experiments allowed the 
identification of about twenty putative MARK4 interactors (Brajenovicet al., 2004). Among 
them, PKCλ and Cdc42 are implicated in cell polarity and TGFβIAF (Transforming Growth 
Factor β-Inducing Anti-apoptotic Factor) is considered an hortologue of Miranda, a protein 
involved in the asymmetric division of neuroblasts in Drosophila. MARK4 also interacts with 
the 14-3-3η isoform (Brajenovicet al., 2004; Angrandet al., 2006). 14-3-3 proteins have a well 
established rolein the control of many cellular processes by binding to phosphorylated proteins. 
14-3-3ηcould thus regulate MARK4 activity or act as a bridge between different pathways. Other 
MARK4 interactors are ARHGEF2, a cytoskeleton binding protein, and Phosphatase 2A, a 
microtubules associated protein that regulates tau (Brajenovic et al., 2004).  
MARK4 protein was also found to co-localise and co-immuoprecipitate with α-, β-, and γ-
tubulin, myosin and actin (Trinczek et al., 2004; Brajenovic et al., 2004). 
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1.7.4 Gene expression and protein localisation 
Few MARK4 expression studies are reported in literature not always with concordant results 
(Kato et al., 2001; Trinczek et al., 2004; Schneider et al., 2004; Moroni et al., 2006). MARK4 is 
ubiquitously expressed, with relevant expression levels in brain and testis. In particular, 
MARK4L appeared highly expressed in testis, brain, kidney, liver and lung (Trinczek et al., 
2004; Schneider et al., 2004; Moroni et al., 2006), while MARK4S expression is predominant in 
testis, heart and brain (Kato et al., 2001; Moroni et al., 2006). In brain, MARK4 protein was 
predominantly observed at the tips of neurite-like processes (Trinczeket al., 2004) while 
immunohistochemistry on rat cerebral cortex and hippocampus showed MARK4L and MARK4S 
expression restricted to neurons of the grey matter (Moroni et al., 2006). 
Exogenous GFP-conjugated MARK4 protein localises in interphase centrosomes in both CHO 
(Chinese Hamster Ovary) and neuroblastoma cell lines. Inactive MARK4 has been reported to 
localise near the nucleus, associated to the endoplasmic reticulum and, once activated, it 
associates with microtubules in the centrosome to exert its functions (Trinczek et al., 2004). 
MARK4 protein has been recently demonstrated to localise at interphase centrosomes also in 
glioma cell lines, and to co-localises with γ-tubulin at all cell cycle phases (Magnani et al., 2009; 
Magnani et al., 2011). This centrosome association was not abolished by depolymerisation of 
microtubules induced by nocodazole, suggesting that MARK4L is a core component of 
centrosomes. Moreover, two novel MARK4L localisation at the nucleolus and the midbody have 
been highlighted (Magnani et al., 2009). 
 
1.7.5 MARK4 in the central nervous system and tumours 
The MARK4 gene was first identified in hepatocarcinoma cells. Indeed, accumulation of β-
catenin in the nucleus, after inactivation of the Wnt/β-catenin pathway, determines increased 
expression of several genes, including MARK4, in hepatocarcinoma cells. These evidences led 
Kato and colleagues to hypothesise that MARK4 could be a downstream component of the Wnt-
signalling pathway (Kato et al., 2001).  
MARK4 was also found transiently up-regulated after ischemic events in brain. Among the 
multitude of gene overexpressed in the injured brain, was also included LKB1 that 
phosphorylates MARK4. Since cell vitality of hepatocytes was strongly reduced after 
experimental overexpression of MARK4S, MARK4S up-regulation in the early stages of an 
ischemic event was then hypothesised to increase neuron death (Schneider et al., 2004). 
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Analysis of chromosomal rearrangements frequently observed in glioma, led to the identification 
of an amplified region in 19q13.2. Interestingly, the amplified region was centromeric to the 
Loss Of Heterozygosity (LOH) area in gliomas (Hartmann et al., 2002) but never deleted in 
these tumours, suggesting the presence of a key gene for cancer cells. DNA sequence of the 
amplified region revealed that it harbours the MARK4 gene (Beghini et al., 2003). Moreover, 
array-CGH (Comparative Genomic Hybridisation) showed MARK4 duplication in a glioblastoma 
cell line (MI-4) (Beghini et al., 2003; Roversi et al., 2006). Further semi-quantitative analysis of 
MARK4 expression in glioma pointed out a MARK4L up-regulation, directly correlated with 
malignancy grade, in 8 tissue samples and 26 cell lines (10 I and II grade, 11 III grade and 5 IV 
grade gliomas). Contrarily, MARK4S appeared highly expressed in normal brain and hardly 
detectable in glioma samples and human neural progenitors. It was therefore suggested that 
MARK4L might be a mitogen protein, necessary for proliferation and thus highly enriched in 
proliferating or undifferentiated cells (Beghini et al., 2003).  
Competitive PCR outlined that MARK4S expression levels increase during neuronal 
differentiation of neural progenitors, while MARK4L expression levels were unchanged in 
differentiated neurons. MARK4S was therefore suggested to be a neuron-specific marker in the 
central nervous system (CNS) and to drive neuronal commitment. 
Our real-time PCR and immunobloting experiments confirmed the overexpression of MARK4L 
in glioma tissues, associated with low levels of MARK4S that appeared inversely correlated with 
tumour grade and cellular de-differentiaton (Figure 12). 
 
 
 
Figure 12. Relative expression of MARK4L (blue bar) and MARK4S (red bar) mRNAs in astrocytomas, 
glioblastomas and GBM CSCs compared to normal brain (set as 1 and represented as a horizontal black line) 
(adapted from Magnani et al., 2011). 
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A high MARK4L/MARK4S ratio also characterised glioblastoma-derived cancer stem cells 
(GBM CSCs), with a MARK4 expression profile comparable to mouse neural stem cells (NSCs) 
(Figure 13) (Magnani et al., 2011).  
 
 
 
 
Figure 13. MARK4 mRNA expression profile in GBM CSCs and NSCs.MARK4L (red bar) and MARK4S (blue 
bar) mRNA expression in human undifferentiated GBM CSCs and mouse undifferentiated NSCs compared to 
human neural progenitor cells (conventionally set as 1) (adapted from Magnani et al., 2011). 
 
 
Furthermore, MARK4 immunohistochemistry on both human and mouse adult and embryonic 
brain, disclosed a peculiar expression of MARK4L in the embryonic ventricular zone and adult 
sub-ventricular zone, both well known regions of neurogenesis. According to real-time and 
immunobloting data, MARK4S was undetectable in these germinal zones, but marked post-
mitotic neurons (Magnani et al., 2011). Overall these evidences suggest that the balance between 
the two MARK4 isoforms is critical for neural differentiation and proliferation. MARK4L 
characterises undifferentiated cells and the expression of MARK4S drives cell differentiation. In 
glioma, a subverted MARK4L/MARK4S ratio may contribute to cellular de-differentiation and 
proliferation during gliomagenesis. 
MARK4 has also been associated with Alzheimer’s disease (AD), on the basis of its kinase 
activity on tau protein, which is crucial in AD pathomechanism, and for its gene localisation 
nearby a locus of susceptibility (ApoE) to AD (Trinczek et al., 2004). A role of MARK4 in AD 
was also confirmed by a recent study that highlighted a strong MARK4 overexpression and 
MARK4-tau interaction in AD brains, correlating with the clinical stages of the disease (Gu et 
al., 2013). 
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1.7.6 MARK4 functions 
MARK4 phosphorylates MAPs, increasing microtubule dynamics, and thus taking part in cell 
cycle control (Brajenovic et al., 2004). MARK4L, given its interaction with microtubules in 
glioma and its localisations at centrosomes and midbody, is suggested to play a role in cell cycle 
progression and in cytokinesis (Magnani et al., 2009). MARK4L overexpression in tumours also 
sustains its role in cell proliferation (Kato et al., 2001; Beghini et al., 2003). On the contrary 
MARK4S may be a neuron-specific marker in the CNS and could drive neuronal commitment 
(Moroni et al., 2006; Magnani et al., 2011). The observed altered ratio of the two MARK4 
isoforms in glioma, suggests that the balance between the two isoforms is carefully guarded 
during neuronal differentiation and that it may represent a target of tumour transformation in 
glioma.  
Recently, other functions of MARK4 have been pointed out. Tang and colleagues found a 
peculiar role of MARK4 in the ectoplasmic specialisation (ES), a centrosome-derived structure, 
during spermatogenesis (Tang et al., 2012). MARK4 was detected at the apical and basal ES 
with restrictive spatio-temporal expression and found to co-localise with markers of the apical 
and basal ES. MARK4 expression was profiledas stage-specific during the epithelial cycle of the 
ES, and MARK4 protein appeared associated with different components of the tubulin 
cytoskeleton. As downregulation of the kinase leads to apical ES disruption and consequent 
detachment of spermatids from the epithelium the authors concluded that MARK4 is likely 
fundamental for the maintenance of the apical ES integrity (Tang et al., 2012). 
MARK4 has also been suggested to play a key role in energy metabolism since MARK4 
deficient mice show hyperphagia, hyperactivity, and hypermetabolism, possibly being protected 
by diet-induced obesity and related complications. MARK4 knockdown appeared to enhance 
insulin-stimulated AKT phosphorylation in metabolic tissues and thus to reduce obesity-
associated insulin resistance (Sun et al., 2012). 
Supporting evidences on the role of MARK4 in proliferation and tumour come from its 
association with the mTORC pathway. MARK4 overexpression significantly inhibits TORC1 
activation through Rag GTPases and phosphorylation of Raptor, key components of mTORC1 
(Li and Guan 2013). However, in this study no discrimination between the two MARK4 
isoforms has been made, even if we speculate that, according to other studies in literature, the 
target of this work was MARK4S, which has been constantly associated with differentiation and 
reduced proliferation.  
MARK4 has also been proposed as critical regulator of the early steps of ciliogenesis. Recent 
evidence associates the MARK4 protein with the basal body and ciliary axoneme in human and 
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murine cell lines and an active function at the level of axonemal extension is suggested (Kuhns 
et al.,2013).  
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2.1 Tissue samples and cell cultures  
2.1.1 Human glioma tissue samples 
A total of 15 human glioma tissue biopsies were provided by Professor Lorenzo Bello 
(Department of Medical Biothecnologies and Translational Medicine, Università degli Studi di 
Milano, Milano). Biopsies were excised from patients who had received no previous 
chemotherapy or radiation treatment, in accordance with a protocol approved by the Internal 
Review Board of the University of Milan’s Neurosurgery department. The specimens were 
stored at -80°C immediately after surgery. Table 1 reports features of the glioma samples under 
study. 
 
SEX/AGE 
at surgery 
TISSUE 
SAMPLE 
HISTOLOGICAL 
DIAGNOSIS 
WHO 
GRADE 
PROGNOSIS mMGMT Del1p Del19q 
M/32 1 Protoplasmic astrocytoma  II (III) alive-no relapses + - - 
N.A. 41 Astrocytoma II N.A. N.E. N.E. N.E. 
M/34 64 Protoplasmic astrocytoma II alive-relapse N.E. - - 
N.A. 94 Astrocytoma II N.A. N.E. N.E. N.E. 
F/52 108 Anaplastic astrocytoma III dead-32 months + - - 
F/35 164 Fibrillary astrocytoma II alive-no relapses + - - 
M/34 216 Protoplasmatic astrocytoma  II alive-relapse + - - 
F/66 5 Glioblastoma IV dead-12 months + + + 
F/72 21 Giant cell glioblastoma IV dead-5 months N.E. N.E. N.E. 
F/65 81 Glioblastoma IV dead-11 months + + + 
M/68 96 Glioblastoma IV dead-18 months + N.E. N.E. 
M/63 113 Glioblastoma IV dead-15 months + - - 
M/44 121 Glioblastoma IV dead-3 months + - - 
M/51 132 Glioblastoma IV dead-26 months - - + 
M/50 194 Glioblastoma IV alive-no relapses - + - 
M/64 207 Glioblastoma IV alive-relapse - - + 
 
Table 1. Clinic and pathological features of astrocytomas (n=7) and glioblastomas (n=9). mMGMT = methylation 
of MGMT gene; Del = deletion; N.A. = not available; N.E. = not evaluated. 
 
2.1.2 Human normal brain 
Normal brain samples (NB) obtained from two male patients operated for intractable epilepsy 
and used as normal controls for real-time and immunoblotting experiments; samples were stored 
at -80°C immediately after surgery. RNA from total human normal brain (MVP Total RNA, 
Human Brain) was also purchased by Stratagene (La Jolla, CA, USA). 
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2.1.3 Cell cultures 
Human Embryonic Kidney 293T (HEK293T) and the oligoastrocytoma G157 (WHO grade II) 
cell lines were used for in vivo splicing assays. G157 cell line has been selected from a panel of 
21 human primary glioma cell lines, obtained from post-surgery specimens and characterised as 
described elsewhere (Magnani et al., 1994; Perego et al., 1994; Beghini et al., 2003; Roversi et 
al., 2006).  
HEK293T cells were grown in DMEM supplemented with 10% fetal bovin serum (FBS), while 
G157 were grown in RPMI with 5% FBS, both with 100 U/ml penicillin (Pen) and 100 U/ml 
streptomicine (Strep) at 37°C in a 5% CO2 atmosphere. Cells were always collected in the 
exponential growth phase.  
Normal Human Neural Progenitor Cells (NHNP) (Lonza, Walkersville, MD, USA) were grown 
in Neural progenitor maintenance bulletkit according to the manufacturer’s protocol, at 37°Cin a 
5% CO2 atmosphere. 
2.1.4 Human glioblastoma-derived cancer stem cell and mouse neural stem 
cells  
Human glioblastoma-derived cancer stem cell lines (GBM CSCs) and a mouse neural stem cell 
line (NSC), both undifferentiated and differentiated, were kindly provided by Dr. Rossella Galli 
(Neural stem cell biology unit, Division of regenerative medicine, stem cell and gene therapy, 
Istituto Scientifico San Raffaele, Milano). 
GBM CSCs and NSCs were characterised as reported (Mazzoleni et al. 2010; Galli et al. 2004; 
Foroni et al. 2007). Briefly, post-surgery tissues from primary glioblastomas or mouse brain 
tissue were dissected, enzymatically digested and dissociated into a single cell suspension. 
Viable cells were plated at clonal density in serum-free, stringent and low-density conditions. 
DMEM/F12 medium added with 20 ng/ml of both EGF and FGF2, was used to allow selection 
away of differentiated/differentiating cells and enriching for the stem cell component (Reynolds 
and Rietze 2006). The resulting neurospheres were analysed and validated for being bona fide 
stem cells, by assessing their ability for long-term proliferation, self-renewal (by subcloning 
experiments), multipotency (by inducing differentiation into the three neural cell lineages) and 
tumorigenicity (by assessing their capacity to give rise to tumours in vivo). 
0622 and 070104 GBM CSCs and NSCs were terminally differentiated in the three major neural 
cell types (astrocytes, oligodendrocytes and neurons) by culturing them in mitogen-free medium 
supplemented with 2% FBS. Immunofluorescence for neural antigens was performed to assess 
differentiation. 
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2.2 Gene expression analysis  
We performed real-time quantitative PCR on cDNAs from tissue samples and GBM CSCs to 
quantify total MARK4 expression levels and from HEK293T and G157 cell lines to outline 
MARK4L and MARK4S expression profile. 
 
2.2.1 RNA extraction  
RNA was extracted from tissues and cells using the TRIreagent (Total RNA Isolation reagent, 
Sigma, Saint Louis, MI, USA), a phenol-guanidine thiocianate solution that dissolves cell 
components leaving nucleic acids intact.  
Tissue specimens were homogenised in an appropriate volume of TRIreagent (according to their 
weight) with a ULTRA-TURRAX T25 homogeniser (Janke & Kunkel, IKA-Labortechnik, 
Staufen, Germany); cells were instead harvested, washed in PBS and resuspended in TRIreagent 
by repetitive pipetting. After 10 min incubation, the homogenates were supplemented with 
chloroform, vigorously shaken and centrifuged at 12,000 g for 15 min at 4°C. Following 
centrifugation the mixture separates into three phases: RNA is in the upper-aqueous phase, DNA 
is in the interphase, while the lower-organic phase contains proteins; RNA was then extracted 
according to manufacturer’s instructions.  
DNase I (RNase-free, New England BioLabs, Inc., Ipswich, MA, USA) was added to RNA to 
remove residual DNA.  
RNA quantity and quality were determined by measuring absorbance at 230, 260 and 280 nm 
with the ND-1000 Spectrophotometer (NanoDrop products, Waltham, MA, USA, by Thermo 
Fisher Scientific, Inc.). 
2.2.2 Reverse transcription PCR (RT-PCR) 
Complementary DNA (cDNA) was obtained from tissues and cell lines by reverse transcription 
PCR (RT-PCR). 500 ng of total RNA from cell lines and 250 ng of total RNA from tissue 
samples were processed using the High capacity cDNA reverse transcription kit (Applied 
Biosystems, Foster City, CA, USA), with random examers, according to the manufacturer’s 
protocol.  
Each sample was reverse-transcribed in two independent reactions. A PCR amplification of the 
housekeeping gene GAPDH was then performed to check the efficiency of RT-PCR. PCR 
conditions and primers used are reported below.  
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PRIMER SEQUENCE Ta 
GAPDH F 5’-ACAACAGCCTCAAGATCATCAG -3’ 
 
62°C 
MARK4 del87 nt R 5’-GGTCCACCACTGACACGTTG -3’  
 
 
2.2.3 Real-time quantitative PCR 
Real-time PCR allows cDNA quantification of a target gene with high accuracy and sensitivity. 
Differently from the traditional PCR reaction, real-time PCR enables the measurement of 
amplified products as the reaction progresses, through the inclusion in the reaction of a 
sequence-specific, fluorescently labelled oligonucleotide probe, called TaqMan, that reports an 
increased in the amount of the target product with a proportional increase in fluorescent signal. 
Therefore, the measured fluorescence reflects the amount of amplified product in each cycle. 
The real-time reaction shows an exponential phase, when the amount of PCR product 
approximately doubles in each cycle, followed by a plateau phase, when one or more of the 
components is/are consumed during the reaction and become(s) limiting.  
The real-time PCR instrument registers the fluorescent signal in the exponential phase, in 
particular at the cycle number when enough amplified product accumulates to yield a fluorescent 
signal that overcomes the background level, called the threshold cycle or CT. At the CT the 
amount of the generated PCR products is directly proportional to the original quantity of the 
target gene cDNA.  
Relative mRNA levels of the target gene may be obtained by relative quantification through data 
normalisation on reference housekeeping genes. 
 
2.2.3.1 TaqMan assays and real-time PCR 
Real-time PCR experiments were performed with the TaqMan Fast Universal PCR Master Mix 
2x No AmpErase UNG and specific TaqMan gene expression assays, all from Applied 
Biosystems. In particular we used inventoried assays for actin β (ID: Hs99999903_m1) and total 
MARK4 (Hs00230039_m1), a pre-developed assay for GAPDH (ID:4333764F) and custom 
assays for MARK4S and MARK4L. Features of the TaqMan assays on demand are provided in 
Table 2: 
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ASSAY PRIMER SEQUENCE PROBE SEQUENCE 
MARK4L 
 
 F5’ CCGAAGGGTCGCAGACGAA 3’ 5’ CCTGAGGTCACAAGTT 3’ 
 R5’ CCGTTTGATCCCAAGGTAGATG 3’ 
 
MARK4S F5’ GTTACCCTCGATCCCTCTAAACG 3’ 5’CAGAACTCTAACCGCTGTGT 3’ 
 R5’ GTTCGTCTGCGACCTGATCTT 3’ 
 
Table 2. Primer and probe sequences for MARK4S and MARK4L custom assays. 
 
Primers and probes for MARK4S and MARK4L assays have been designed to specifically 
amplify only one isoform and, when possible, at the exon-exon boundary to avoid genomic DNA 
amplification. In detail, MARK4S forward primer and probe bind to the alternative exon 16, 
specific of the S isoform, and reverse primer is localised at the exons 16-17 boundary. MARK4L 
forward primer binds to the exons 15-17 junction, while the probe and reverse primer span exon 
18. 
A reaction mix was prepared as follow for each sample and assay:  
  
    
 
 
 
Reactions were run on the StepOne Real-Time PCR System (Applied Biosystems), under the 
following conditions:  
 
All samples were reverse transcribed in two independent reactions and loaded in triplicate in 
real-time experiments.  
 
 
2.2.3.2 Relative quantification analysis 
CT values from each triplicate were recovered from the StepOne Software (v1.2; Applied 
Biosystems) and then analysed using two different methods: the 2
-ΔΔC
T method (Livaket al., 
2001) for cell lines, and the geNorm method (E
-ΔC
T) (Vandesompele 2002) for tissue samples 
and GBM CSCs.  
95°C 95°C
20’’ 3’’
60°C
20’’
40 cycles
H20   2.5 µl   
 Master Mix (2x) 5.0 µl   
 Assay (20x)  0.5 µl 
            cDNA (1.5 fold diluted)   1.5 µl 
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In both cases, MARK4S and L expression levels were normalised on housekeeping genes and 
then referred to a sample chosen as reference (NHNP for cell lines and normal brain for tissue 
specimens and GBM CSCs), whose expression value was set as 1.  
According to Livak method, for each sample the target gene expression level = 2
-ΔΔC
T 
 where: ΔΔCT = sample ΔCT – reference ΔCT; 
   sample ΔCT = [target gene CT – control gene CT] in the sample; 
   reference ΔCT = [target gene CT – control gene CT] in the reference; 
   (sample and reference ΔCT correspond to the mean value between  
   the ΔCTs of the two independent RT reactions).  
In the geNorm method, instead, multiple control genes are used and the amplification efficiency 
(E, set as 2 in the 2
-ΔΔC
T method) is calculated for each assay, taking into account the specific 
efficiency of each assay.  
Values with standard deviation exceeding 0.5% or standard error exceeding 0.3% were excluded 
and experiments repeated. Real-time expression data were expressed as mean ± standard 
deviation. 
 
2.2.3.3 Statistical analysis  
The Kruskal-Wallis and the 1-sample Wilcoxon tests were used for statistical analysis performed 
with the StatistiXL 1.8 software for Microsoft Excel (www.statistixl.com). Differences between 
experimental groups were considered significant when p < 0.05. 
 
2.2.4 TaqMan assay validation 
 
Amplification efficiency and stability of TaqMan gene expression assays (total MARK4, 
MARK4L, MARK4S, GAPDH, actin β, RPLP0 and HPRT) were evaluated before relative 
quantification analysis.  
 
2.2.4.1 Assay amplification efficiency 
Assay amplification efficiency is essential to allow an accurate and reproducible quantification 
of target cDNA. This optimisation was achieved by running serial dilutions of a cDNA pool of 
the samples under study and using the resulting CT to generate a standard curve. The standard 
curve was obtained by plotting logarithmic dilution values of each concentration against the 
relative CT value. The equation of the linear regression line was then used to evaluate 
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amplification efficiency (E). E was calculated according to the E=10
-1/S
 formula, where S is the 
slope of the regression line. As reported in Table 3 the resulting efficiency was near 2 for all the 
analysed assays. A 100% amplification efficiency has an E value of 2 since, ideally, PCR 
product quantity should double at every PCR cycle. Therefore, all tested assays have a good 
amplification efficiency.  
 
2.2.4.2 Assay stability 
To assess assay stability, the ability to amplify the target gene with the same efficiency in a 
broad range of sample dilutions, we calculated the relative quantity (Q) of each gene in the 
cDNA serial dilutions, according to the following formula Q=E
-ΔC
T (ΔCT =sample CT – reference 
CT), and then we sorted the assays on the basis of their stability using the GeNorm software 
(version 3.5; http://medgen.ugent.be/jvdesomp/genorm/). GAPDH and actin β were chosen as 
control genes, since they were the most stable and showed an amplification efficiency, in our 
pool of samples, more similar to that of our target genes. In detail, for cell lines, given their 
homogenous nature, we used a single reference gene (GAPDH), while GAPDH and actin β were 
used in combination for tissue samples and GBM CSCs.  
 
 
ASSAY DILUTIONS CT S E ΔCt 
RELATIVE 
QUANTITY 
GAPDH 
1 16.52 -3.30 2.01 0.00 1.00 
1:10 19.73   3.21 0.11 
1.100 23.05   6.52 0.01 
1:1000 26.41   9.89 0.00 
 
   ACTB 
1 16.78 -3.65 1.88 0.00        1.00 
1:10 20.35   3.57 0.11 
1.100 24.02   7.25 0.01 
1:1000 27.71 
 
  10.93 0.00 
RPLP0 
1 17.74 -3.28 2.02 0.00 1.00 
1:10 20.85   3.10 0.11 
1.100 24.18   6.44 0.01 
1:1000 27.56 
 
  9.82 0.00 
HPRT 1 21.78 -3.31 2.00 0.00 1.00 
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1:10 24.95   3.18 0.11 
1.100 28.20   6.43 0.01 
1:1000 31.74 
 
  9.96 0.00 
 1 26.19  -3.32 2.00 0.00 1.00 
MARK4 1:10 28.84   2.65 0.11 
 1:100 32.30   6.11 0.01 
 
1:1000 36.11 
 
  9.92 0.00 
MARK4L 
1 23.75 -3.40 1.97 0.00 1.00 
1:10 27.00   3.25 0.11 
1.100 30.50   6.75 0.01 
1:1000 33.92 
 
  10.17 0.00 
MARK4S 
1 28.00 -3.54 1.92 0.00 1.00 
1:10 31.26   3.25 0.11 
1.100 35.00   6.99 0.01 
1:1000  N.D.        /    / 
 
Table 3. Assay amplification efficiency (E). For each assay, CT values, corresponding to serial dilutions 
of a pool of glioma cDNAs, are displayed. S, slope of the interpolating line; N.D., undetermined. 
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2.3 Bioinformatic prediction of splicing factor binding sites and 
analysis of conservation 
Putative binding sites for splicing factors in MARK4 IVS15 and the proximal region of IV16 
were predicted using SFmap (http://sfmap.technion.ac.il/) and SpliceAid 
(http://193.206.120.249/splicing_tissue.html). The two web resources use different approaches. 
SFmap predicts splicing factors binding sites by the implementation of the COS(WR) algorithm 
(Akerman et al., 2009), which analyses similarity scores for a given regulatory motif on the basis 
of information derived from its sequence environment and its evolutionary conservation. The 
most important advantages of this algorithm are that it is very accurate in prediction and it 
calculates standardised scores for any motif, so that the predictions of different binding sites are 
comparable (Paz et al., 2010). On the other hand, SpliceAid is a database of strictly 
experimentally assessed RNA sequences bound by splicing factors. To date a total of 680 target 
sites and 54 proteins have been annotated (Piva et al., 2009). 
Conservation analysis of the predicted binding sites for splicing factors was performed with 
Clustal Omega, a web resource that allows multiple alignments of sequences exploiting the 
multiple progressive alignment method. Briefly, the program initially starts to align short 
portions of the query sequences that appear more correlated, then it proceeds aligning the 
remaining parts of the sequences without changes in the previous preliminary alignment. By this 
way the program is able to output the alignment with the maximum score (Sievers et al., 2011). 
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2.4 Protein expression analysis 
2.4.1 Protein extraction 
Tissue samples were homogenised using an ULTRA-TURRAX T25 homogeniser (Janke & 
Kunkel) in 400 µl lysis buffer/50 mg, whose composition is reported below. 
 
 
 
 
 
Suspensions were placed on ice for 30 min with occasional inversion to ensure complete lysis. 
Lysates were then spun at 12,000 g for 30 min at 4°C, to prevent protein degradation, and the 
supernatant (whole cell lysate) was stored at -20°C.  
Protein concentration was determined using the BCA Protein Assay Kit (Pierce, Rockford, IL, 
USA), according to the manufacturer’s protocol, and the ND-1000 Spectrophotometer 
(NanoDrop products). 
 
2.4.2 Immunoblotting 
Immunoblotting enables separation of proteins according to their molecular weight and the 
identification of the presence of a specific protein, its size and its relative expression level. 
For each sample 30 µg of extracted proteins were supplemented with reducing SDS (Sodium 
Dodecyl Sulphate) loading buffer (Blue loading buffer pack, Cell Signaling Technology, Inc., 
Beverly, MA, USA) and denatured at 99°C for 3 min.  
Proteins were then resolved by SDS PolyAcrylamide Gel Electrophoresis (SDS-PAGE) (4% 
stacking gel at 100V for 10 min and 10% resolving gel at 130V 100 min). Proteins were then 
transferred by electroblotting to a PVDF (Polyvinylidene fluoride) membrane (Roche 
Diagnostic, Manheim, Germany). Mini-PROTEAN Tetra cell and Trans-blot semi-dry 
electrophoretic transfer cell (both Bio-Rad, Hercules, CA, USA) were respectively used for 
electrophoresis and electroblotting (10V, 30 min) as instructed by the manufacturer. The 
Biotinylated protein ladder (Cell Signaling Technology) and ColorBurst electrophoresis marker 
(Sigma) were used as molecular weight standards. 
Membranes were then washed twice in PBS-T 0,3% (PBS ph7.5: 100 mM NaCl, 80 mM 
HNa2O4P, 20 mM NaH2PO4 with 0.3% Tween20), and non-specific binding was blocked by 
incubating the membranes in 5% skimmed milk, PBS-T 0,3% for 1 h at room temperature (RT), 
150 mM NaCl 
50 mM Tris pH 7.5 
1% NP-40,  
0.25% deoxycholic acid, protease inhibitor cocktail (Complete 
EDTA-free, from Roche Diagnostic, Manheim, Germany) 
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in gently agitation. The membranes were incubated with primary antibodies in PBS-T at 4°C 
overnight in agitation. 
 
 
 
 
 
After five washes in PBS-T 0,3%, membranes were incubated with secondary antibodies in PBS-
T 0,3% at RT for 1 h in agitation. Secondary antibodies are conjugated to HRP (Horse Radish 
Peroxidase) and an anti-biotin antibody was added to detect the biotinylated protein ladder. 
 
 
 
 
 
For quantification, the membranes were cut horizontally immediately after the blocking step and 
incubated with the appropriate antibodies. 
After four washes in PBS-T 0,3 % and two washes in PBS, membranes were incubated 5 min 
with a peroxide/enhancer solution (Westar ηC,Cyanagen, Bologna, Italy) and blots were scanned 
using the Gbox Chemi XT4 system (Syngene, Cambridge, UK). 
2.4.3 Semi-quantitative analysis 
To compare PTB and MARK4L protein expression in different tissue samples or cell lines we 
did a relative quantification analysis, using GAPDH as normaliser. For each sample two 
immunoblotting experiments were performed maintaining unaltered conditions. For 
quantification, blot images were acquired at low pixel saturation levels, so that the acquired 
signal intensity was directly proportional to the emitted chemiluminescent intensity. Images were 
analyzed with the Gene Tools Gel Analysis software (Syngene). Each lane (including both PTB 
or MARK4L and GAPDH bands) was selected and lane profile plots were automatically 
generated for each band in the lane, displaying a two-dimensional graph reporting peaks 
corresponding to gel bands (on the X-axis) and their relative pixel intensities (on the Y-axis). 
After automatic subtraction of the background the peaks area was measured in square pixels. For 
data normalisation, in each sample MARK4L or PTB area value was divided by the respective 
GAPDH value.  
Rabbit anti-MARK4L (Genscript Corporation, Piscataway, NJ, USA)      1: 1,5000  
Mouse anti-PTB (ab30317; Abcam, Cambridge, UK)      1: 1,200 
Mouse anti-GAPDH (ab8245, Abcam)     1: 10,000 
Goat anti-rabbit IgG-HRP (sc-2004; Santa Cruz Biotechnology)  1: 10,000 
Goat anti-mouse IgG-HRP (sc-2005; Santa Cruz Biotechnology)    1: 25,000 
Anti-biotin, HRP-linked antibody (Cell Signaling)    1: 2,500 
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2.5 Splicing minigene assay 
Minigene constructs are a useful tool for identification and in vivo analysis of cis-regulatory 
elements and trans-acting factor involved in alternative splicing regulation. In particular, 
minigenes are commonly used to : i) identify splice sites implicated in the mechanism of exons 
recognition and splicing; ii) identify exonic/intronic splicing enhancers and silencers; iii) 
determine the effect of an allelic variant or a mutation on splicing; iv) identify cell-specific 
splicing events and the underneath elements; v) identify binding sequence for a specific splicing.  
2.5.1 Minigene design 
We cloned the genomic fragment corresponding to MARK4 exons 15, 16 and 17 and the 
intervening sequences (IVS) 15 and 16 in the mammalian expression vector pcDNA3.1 
(Invitrogen, Camarillo, CA, USA) (Figure 14). The fragment was PCR amplified from DNA of 
HEK293T cells, extracted with the QIAmp DNA mini kit (Qiagen S.P.A., Milano, Italy), with 
specific primers containing unique restriction enzyme sites at their 5’-ends, to allow the insertion 
of the amplified fragment into the multicloning site of pcDNA3.1 (Figure 14). 
 
 
Figure 14. Schematic representation of MARK4 exons 15-17, IVS15 and IVS16 cloning into the 
mammalian expression vector pcDNA3.1. 
 
In particular, the forward primer contained the restriction site for HindIII (AAGCTT) and the 
reverse primer the restriction site for EcoRI (GAATTC). Since many restriction enzymes do not 
cut efficiently when the restriction site is at the end of the molecule, six non-specific nucleotides 
have been included as the first nucleotides of the primers. These nucleotides are followed by the 
restriction site and 12 nucleotides complementary to the 5’-end of exon 15 and the 3’-end of 
exon 17,respectively (Table 4). 
PRIMER SEQUENCE 
MARK4 cl 15-17 F 5’-ATAACCAAGCTTCTCAGGCACCCC-3’ 
 
MARK4 cl 15-17 R 5’-CGCACTGAATTCCTTGTGACCTCA-3’ 
 
Table 4. Sequences of primers used for MARK4 exons 15-17 and interposed introns cloning. Non 
specific nucleotides are bolded and restriction site sequences are underlined. 
CMV
HindIII
Exon 15
IVS15
Exon 16 Exon 17
IVS16
EcoRI
188 bp 1588 bp279 bp 80 bp 45 bp
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The PCR reactions were performed with the high fidelity polymerase Phusion Taq (Finnzymes, 
Espoo, Finland), to avoid insertion of mutations, and using a specific buffer for GC-rich 
sequences (GC Buffer) since the MARK4 sequence of interest appeared very difficult to amplify, 
probably because of the nucleotide composition. 
 
 
 
 
 
 
 
PCR amplicons were then run on a 2% agarose gel to verify their molecular weight. PCR were 
precipitated by adding 1/10 of volume of sodium acetate 2.5 M pH 5.2 and two volumes of 100% 
cold ethanol O.N at -20°C. Precipitated PCR were then spun at 13,000 g for 30 min at 4°C and 
washed twice in 70% cold ethanol. 
Both the empty pcDNA3.1 vector and the precipitated MARK4 PCR were cut with HindIII and 
EcoRI restriction enzymes (Promega, Madison, WI, USA) as follows:  
 
 
 
 
 
 
 
 
Digested vector and PCR were run on a 1% agarose gel, excise and gel purified with the 
MinElute Gel Extraction kit (Qiagen) according to the manufacturer’s protocol. Eluted bands 
were then quantify with the ND-1000 Spectrophotometer (NanoDrop products) and ligated with 
the T4 DNA Ligase (Promega) maintaining a vector:insert molar ratio of 1:3 as reported below: 
 
 
 
 
 
GC Buffer  5 μl 
dNTPs (20 mM)1 μl 
DMSO  2    μl 
MK4 cl 15-17 F 1,2 μl 
MK4 cl 15-17 R         1,2 μl 
DNA                           80 ng 
Taq   0,5 μl 
H2O          to 50  μl 
vector/insert  500 ng 
Buffer E     2  μl 
BSA   0.2  μl      1 h 15 min 37°C 
EcoRI   0.5  μl 
HindIII  0.5  μl  
H2O                          to 20 μl 
10X Buffer  2  μl 
pcDNA3.1           60.1 ng     
MK4 cl 15-17    50 ng        1 h 16°C 
T4 DNA Ligase         0.5  μl  
H2O                         to 10 μl 
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2.5.2 Transformation and plasmid DNA extraction 
E. coli TOP10 were transformed with the whole ligation reaction. Cloning and transformation of 
the selected MARK4 sequence was particularly hard, probably because of the nucleotide 
composition of the sequence with multiple repeated stretches that favour plasmid recombination. 
TOP10 were selected among different available E. coli strains, after multiple transformation 
experiments, to obtain a higher transformation efficiency. Briefly, 100 μl of chemically 
competent TOP10 were incubated on ice with the whole ligation reaction for 20 min. Bacteria 
were heat shocked at 42°C for 2 min and then, after addition of 1 ml of LB broth, they were 
grown at 37°C for 1 h with shaking at 230 rpm. Transformed bacteria were pelletted at 6,000 
rpm for 5 min at room temperature and then plated on LB agar plates supplemented with 100 
μg/ml Ampicillin (Sigma) for O.N growth at 37°C.  
The day after three colonies were selected and grown in 3 ml LB broth O.N at 37°C with shaking 
at 230 rpm. Plasmid DNA was then extracted using the PureYield
TM
 Miniprep System 
(Promega) and quantify with the ND-1000 Spectrophotometer (NanoDrop products).  
To verify the presence of the MARK4 insert, its correct orientation and the absence of mutations 
the extracted plasmids were PCR amplified and sequenced. GoTaq polymerase and reagents 
from Promega were used for PCR amplification, while Big DyeTerminator v.3.1 Cycle 
Sequencing Kit (Applied Biosystems) was used for sequencing. 
 
2.5.3 Transfection and splicing assay 
MARK4 wild type minigene was transfected in HEK293T and G157 cells to perform splicing 
assays. Cells were plated in Petri dishes of 35 mm at a concentration of 500,000 cells and grown 
in DMEM supplemented with 10% fetal bovin serum (FBS) for HEK293T or in RPMI with 5% 
FBS for G157, in both cases without antibiotics, at 37°C in a 5% CO2 atmosphere. After 24 h 
cells were transfected with the MARK4 minigene splicing vector. The MARK4 minigene (1 μg) 
was incubated with 6 μl of X-tremeGENE HP DNA Transfection Reagent (Roche) in 200 μl 
DMEM or RPMI without FBS and antibiotics for 20 min at RT. The transfection reaction was 
then gently added to the cells after replacing the medium. After 24 h RNA was extracted from 
transfected cells using TRIreagent (Sigma) and treated with DNaseI (New England Bio-Labs, 
Inc.) as previously described (see 2.2.1). After quantification by the ND-1000 Spectrophotometer 
(NanoDrop products), 250 ng of total RNA were reverse transcribed using the High capacity 
cDNA reverse transcription kit (Applied Biosystems) as previously described (see 2.2.2). To 
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verify the efficiency of reverse transcription and the absence of genomic DNA contamination a 
PCR for GAPDH was preformed (see 2.2.2).  
Splicing of the MARK4 minigene was analysed by RT-PCR with primers specifically designed 
to amplify the transcripts derived from the minigene. In particular, the forward primer binds to 
MARK4 exon 15, while the reverse primer is complementary to a pcDNA3.1 portion that is 
transcribed, corresponding to the bovine growth hormone (BGH) polyadenylation signal. 
Primers sequences are reported below: 
 
 
PRIMER SEQUENCE 
MARK4 PSTK10 F 5’-CTGACCTCCAAACTGACCCG-3’ 
 
MARK4 BGH R 5’-GGCTGGCAACTAGAAGGCAC-3’ 
 
 
2.5.4 MARK4 splicing minigene mutagenesis 
To identify splicing regulatory sequences localised in IVS15 involved in MARK4 alternative 
splicing, serial deletions were performed in the MARK4 splicing minigene vector. Two different 
approaches were used to obtained the designed deletions: excision of a portion of the minigene 
and re-synthesis of the excised portion with the desired deletion using partially complementary 
primers; alternatively the QuickChange II XL Site-Directed Mutagenesis kit (Agilent, Santa 
Clara, CA, USA) was used.  
The first approach was used to make the deletion of the last 82 nucleotides of MARK4 IVS15. 
We designed a reverse primer with, starting from the 5’-end, the restriction site for the 
endonuclease enzyme Bgl2, 7 nucleotides corresponding to the 5’-end of the exon 16, the two 
last bases of IVS15 and 11 nucleotides corresponding to the MARK4 IVS15 sequence upstream 
the deletion (Table 5). The forward primer was the same used for the wt MARK4 minigene 
vector. The desired sequence was PCR amplified from MARK4 wt minigene using the Phusion 
Taq (Finzymes) and the primers reported in Table 5 and then precipitated by ethanol-sodium 
acetate as previously reported (see 2.5.1). Both MARK4 wt minigene and the newly synthesised 
insert were digested with HindIII for 3 h at 37°C, then they were precipitated by ethanol-sodium 
acetate and digested with Bgl2 endonuclease enzyme for 3 h at 60°C. Precipitated digested 
vector and insert were then ligated and used in transformation experiments as reported in section 
2.5.2.  
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PRIMER SEQUENCE Ta 
MARK4 del87 nt F 5’-ATAACCAAGCTTCTCAGGCACCCC-3’ 
 
68°C 
MARK4 del87 nt R 5’-CGCACTGAATTCCTTGTGACCTCA-3’  
 
Table 5. Primers and annealing temperature used for deletion of 87 nucleotides of IVS15 in MARK4 minigene. 
 
 
For all other deletions the QuickChange II XL Site-Directed Mutagenesis kit (Agilent) was used 
following manufacturer’s instructions. Primers were designed with the specific QuickChange 
primer design tool (available online at www.genomics.agilent.com/primerDesignProgram.jsp) 
(Table 6). Briefly, PCR products were digested with Dpn I to remove template from the reaction 
and then 2 μl were used for transformation of XL10-Gold ultracompetent E. Coli strain (Qiagen). 
After 30 min incubation of the transformation reaction on ice, cells were heat shocked for 30 
seconds at 42°C and then grown in NZY
+
 broth for 1 h at 37°C with shaking at 230 rpm. 
Transformed cells were then plated on LB agar plates with 100 μg/ml Ampicillin and grown 
O.N. at 37°C. Plasmid extraction and sequencing were performed as previously described in 
section 2.5.2. 
 
PRIMER SEQUENCE 
MARK4 delPTB F 5'-TACCCCAACATTTCC------CTCCTCCTCCTCCTC-3' 
MARK4 delPTB R 5'-GAGGAGGAGGAGGAG------GGAAATGTTGGGGTA-3’ 
MARK4 del15prox F 5'-GTACCCCAACATTTCC------CCTCGTTTCCTCCTCC-3'   
MARK4 del15prox R 5'-GGAGGAGGAAACGAGG------GGAAATGTTGGGGTAC-3' 
MARK4 del32 nt F 5’-GTACCCCAACATTTCC------TCCTCCTCCTTTCCTC-3’ 
MARK4 del32 nt R 5’-GAGGAAAGGAGGAGGA------GGAAATGTTGGGGTAC-3 
 
Table 6. Primers used for deletions in IVS15 of MARK4 minigene vector. 
 
All mutated MARK4 minigenes were transfected in both HEK293T and G157 cell lines to 
perform splicing assays. Splicing of the mutated minigene was evaluated by RT-PCR as 
previously reported in section 2.5.3. 
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2.6 Electrophoretic Mobility Shift Assay (EMSA) 
Electrophoretic mobility shift assays were performed to evaluate in vitro interaction of splicing 
regulators with the MARK4 IVS15. Further mass spectrometry experiments are in progress to 
identify proteins bound to MARK4 mRNA in the shifted band. 
 
2.6.1 MARK4 intron 15 in vitro RNA synthesis 
A single strand RNA corresponding to 71 nucleotides of the polypyrimidine tract of IVS15 was 
in vitro synthesised by means of the T7 Quick High Yield RNA Synthesis Kit (New England 
BioLabs) using a forward primer containing the T7 promoter sequence at the 5’-end to obtain a 
single strand molecule of MARK4 IVS15 RNA (Table 7). 
 
 
PRIMER SEQUENCE 
MARK4 EMSA F 5’-TAATACGACTCACTATAGGGTCTCCTGTACCCCAACA-3’ 
MARK4 EMSA R 5’-GGAAAGGAGGAGGAG-3’ 
 
Table 7. Primers sequences used for MARK4 IVS15 RNA in vitro synthesis. The T7 promoter sequence is 
underlined. 
 
 
Reactions conditions were as follow: 
 
 
 
 
 
Synthesised RNA was then extracted with phenol-chloroform and precipitated in ethanol 
according to manufacturer’s instructions. Purified RNA was dosed by ND-1000 
Spectrophotometer (NanoDrop products). 
NTP buffer mix                      10 μl 
MARK4 wt minigene              1 μg    37°C O.N. 
T7 RNA polymerase mix         2 μl 
H2O DNAse/RNAse free to   30 μl 
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2.6.2 MARK4 RNA 3’-end biotinylation 
MARK4 IVS15 RNA was biotinylated at the 3’-end to performed non-radioactive EMSA. We 
used the RNA 3' End Biotinylation Kit(Pierce) under the following conditions 
 
 
 
 
 
 
 
 
 
Biotinylated RNA was then extracted by chloroform:isoamyl alcohol and precipitated in 10μL of 
5M NaCl, 1μL of glycogen, and 300μL of ice-cold 100% ethanol at -20°C for 1 h. 
 
2.6.3 EMSA 
Non-radioactive EMSA experiments were performed using the LightShift Chemiluminescent 
RNA EMSA Kit (Pierce). Three binding reactions were set up: 1) only MARK4 biotinylated 
RNA, used to define the position of unshifted EMSA band; 2) MARK4 biotinylated RNA 
incubated with cell lysate, to identify possible shifted band by comparison with reaction 1; and 
3) MARK4 biotinylated RNA incubated with cell lysate and 200-fold molar excess of unlabeled 
MARK4 RNA, to understand if the observed shift results from a specific protein-RNA 
interaction. Reactions were performed as follow: 
 
Reagents 
Reaction 
1 2 3 
10X Binding Buffer 2 μl 2 μl 2 μl 
tRNA (10 mg/ml) 0.2 μl 0.2 μl 0.2 μl 
MARK4 unlabeled RNA - - 10 μM 
HEK293T protein extract - 3 μg 3 μg 
MARK4 biotinylated RNA 2 nM 2 nM 2 nM 
Nuclease-free water to 20 μl to 20 μl to 20 μl 
 
10X RNA Ligase Reaction Buffer   3 μl 
RNase Inhibitor     1 μl 
MARK4 IVS15 RNA             50 pmol 
Biotinylated Cytidine (Bis)phosphate  1 μl         16°C O.N 
T4 RNA Ligase     2 μl 
30% PEG               15 μl 
Nuclease-free water                              to 30 μl 
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Binding reactions were incubated 30 min at R.T. and then loaded on a 8% native polyacrylamide 
gel in 0.5X TBE (pre-run for 1 h in 0.5X TBE) after addition of 5 μl 5X Loading Buffer. After 1 
h run at 100 V the gel was transferred on a nylon membrane (GE Healthcare) soaked in 0.5X 
TBE for at least 10 min. Transfer was performed with the Trans-blot semi-dry electrophoretic 
transfer cell (Bio-Rad) for 30 min at 10 V. The membrane was then crosslinked with a hand-held 
UV lamp (254 nm) for 5 min at a distance of 0.5 cm. Detection of biotin-labeled RNA was 
performed according to the manufacturer’s instructions and images of the membranes were 
acquired with the Gbox Chemi XT4 system (Syngene). 
 
  
 
 
 
 
 
 
Results 
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3.1 Alternative splicing as regulator of MARK4 expression 
 
The identification of a MARK4L/MARK4S imbalance in glioma, derived from the 
overexpression of the alternative MARK4L isoform to the detriment of the canonical MARK4S, 
and not imputable to genomic mutations (Magnani et al., 2011), prompted us to hypothesise an 
alteration at the post-transcriptional level responsible for the observed MARK4 isoforms altered 
ratio. 
The observation that the MARK4L/MARK4S ratio is carefully guarded during neural 
differentiation and that a switch from MARK4L expression to MARK4S drives neuronal 
commitment and terminal differentiation (Moroni et al., 2006; Magnani et al., 2011), put on 
scene alternative splicing as the physiological mechanism for MARK4 isoform expression 
regulation according to cell differentiation hinting it might go awry during gliomagenesis. A 
splicing regulation of isoforms expression implies that no differences in the total expression of 
mRNA are observed, even if the relative quantity of the single isoforms differ between samples. 
We thus performed real-time quantification of total MARK4 as starting point to define the role 
of alternative splicing in the regulation of MARK4 isoforms expression in normal and 
transformed cells. 
 
3.1.1 Total MARK4 mRNA expression profile in glioma tissues and 
glioblastoma-derived cancer stem cells  
Real-time PCR analysis on 7 astrocytomas (A) (II/III WHO grade), 8 glioblastomas (GBM) (IV 
grade) and three glioblastoma-derived cancer stem cells (GBM CSCs) compared to human 
normal brain, did not show, despite the heterogenous expression of total MARK4,significant 
differences in the expression of total MARK4among the three subgroups (p = 0.07 at Kruskal-
Wallis test) (Figure 15). Total MARK4 expression levels are comparable to those observed in 
normal brain (p > 0.05 at Wilcoxon test) even if, within the same glioma samples (A, GBM and 
GBM CSCs), the relative expression of the two MARK4 isoforms was significantly different 
from normal brain, as reported in Magnani et al., 2011. A slight decrease in MARK4 expression 
is apparent when considering the mean values of the single subgroups but no correlations 
between MARK4 expression levels and molecular diagnostic and prognostic markers of glioma 
samples could be retrieved according to Kruskal-Wallis test. 
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These evidences suggested that the observed altered ratio in MARK4 isoforms expression is not 
due to alterations in the MARK4 gene transcription, but probably in post-transcriptional 
mechanisms. 
 
 
 
Figure 15. Relative expression levels of MARK4 total mRNA in astrocytomas (A), glioblastomas (GBM) and 
glioblastoma-derived cancer stem cells (GBM CSCs) compared to human normal brain (conventionally set as one 
and represented by a horizontal black line). Data are presented as mean ± standard deviation of three independent 
experiments.  
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3.2 Bioinformatic identification of putative splicing regulatory 
sequences in MARK4 mRNA 
 
We thus performed bioinformatic analysis of the MARK4 mRNA region involved in alternative 
splicing to identify putative regulatory sequences targeted by trans-acting factors, i.e SR or 
hnRNP proteins.  
Since it has been reported that also splicing regulatory sequences, like other regulatory elements, 
are conserved across divergent species (Sorek and Ast, 2003), we also evaluated the conservation 
between human and mouse of the regulatory sequences identified by bioinformatic analysis.  
 
3.2.1 Identification of PTB binding sites in MARK4 introns 15 and 16 
To identify putative regulatory sequences, in MARK4 mRNA, bound by splicing regulators, we 
used SFmap (http://sfmap.technion.ac.il/) and SpliceAid 
(http://193.206.120.249/splicing_tissue.html). These bioinformatic tools were chosen among the 
free available, because they also search for negative regulators of alternative splicing belonging 
to the hnRNP family. Indeed, given the mechanism of MARK4 alternative splicing and the 
observed altered ratio of the two isoforms in glioma, we suspected a role of hnRNP in the 
regulation of exon 16 skipping in both physiological and pathological conditions. The use of 
both prediction tools revealed the presence of a multitude of putative regulatory sequences 
falling in the two main classes of positive and negative splicing regulators (Table 8 and Figure 
16). We then selected out of the sites located in the introns flanking the alternative MARK4 exon 
16, only those predicted to induce exon skipping and reported to play a role in neural 
differentiation and gliomagenesis. Three putative binding sites for PTB were indentified in 
MARK4 IVS15 and IVS16 and appeared of particular interest, given the fundamental role of 
PTB in the proliferation of glial cells and in tumour transformation (Boutz et al., 2007). In detail, 
two putative PTB binding sites are located upstream and one downstream the alternative exon 16 
(Figure 17). The putative PTB binding sites indentified in both introns flanking exon 16 
(highlighted in red) are compatible with all PTB mechanisms of alternative splicing as 
summarised in the Introduction (see1.6.3). In particular, the intronic sequence just upstream exon 
16that includes one of the putative PTB binding sites is a long polypyrimidine tract, that 
represents the proper sequence environment for PTB activity, and is compatible with PTB 
mechanism of action by competition. Also the other identified sequences may be target of PTB 
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binding, allowing skipping of MARK4 exon 16 by propagation or looping, starting from the high 
affinity binding of PTB at the polypyrimidine tract (see Figure 10 of Introduction).  
 
 
 
 
A
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Table 8. Putative regulatory elements, including both positive and negative regulators, identified by SFmap in 
MARK4 IVS15 (A) and the 5’ portion of IVS16 (B). Scores of the probability that the indicated factor is really 
involved in alternative splicing are reported. Negative regulators are boxed in yellow. Putative PTB binding 
sequences are boxed in red. 
 
B
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Figure 16. Putative regulatory elements identified by SpliceAid in IVS15 and in the 5’ portion of IVS16 of 
MARK4. The regulatory factors are indicated by colored boxes, with positive splicing regulators upon and negative 
regulators below the intronic sequence. The height of the boxes is proportional to the probability (score reported on 
the left) that the factor might be really involved in alternative splicing. The PTB binding sites are pointed by the red 
arrows. 
 
 
 
Figure 17. Putative PTB binding sites (red) identified in MARK4 IVS15 and IVS16 flanking the alternative exon 
16. Exons sequence is shaded in grey and the polypyrimidine tract in intron 15 is highlighted in yellow. 
B
MARK4 IVS15
MARK4 IVS16
CTCAGGCACCCCACGGGTGCCCCCTGCCTCCCCCTCCAGTCACAGCCTGGCACCCCCATCAGGGGAGCGGAGCCGCCTGGCACGCGGTTCCACCATCCGCAGCACCT
TCCATGGTGGCCAGGTCCGGGACCGGCGGGCAGGGGGTGGGGGTGGTGGGGGTGTGCAGAATGGGCCCCCTGCCTCTCCCACACTGGCCCATGAGGCTGCACCCC
TGCCCGCCGGGCGGCCCCGCCCCACCACCAACCTCTTCACCAAGCTGACCTCCAAACTGACCCGAAGGTGAGCTCCGCGGGGATGGCAGGGGCAGGGCGGGGCGG
GGGGCCGATGGGACCTAACCTGTCTTCCACTCTGCTCTGTCTCCTGTACCCCAACATTTCCTCTTCCTCCTCCTCCTCCTCCTCGTTTCCTCCTCCTCCTCCTCCTTTCCTCC
TCCCCTGTCACCCCTCACCTCCCTCCTCACACTGCAGGGTTACCCTCGATCCCTCTAAACGGCAGAACTCTAACCGCTGTGTTTCGGGCGCCTCTCTGCCCCAGGGATCC
AAGATCAGTAAGTCCCGTCCATGCCCTGTTCTCGCTGGCTCTGCCTCCCTGCCTGCATGTCTGACCTGTGTGTGCGGGCATTGGGAGGGGGCTCTGTGGATGTGAGG
GTCTGTGCGTGGGGTCTGGTTGTTCATTTACTCACAGAAGCACAGCCTATGGAGCCAGACTCGGGGGTTCAAATGGCAGCTCTGCCAAGTGACCTTGAGCAAGTCAC
TCAAGGTCTCTGGGCCTGGTTTTCCTCTTCTGTAAAATGGTTATAGTAATAACAATACCTGTCTCCTAGGGTTATTGTGAGGACTAAATGAAGTGACGTATGGACTGA
GCGTAGAACATTGCCTTGGAAAGTGCTTTACATGTGTATTAGTTATTAATTGCTATTATTCATTGAGCCCCTACTGTGTGCCTGGCACTGTCCTAGGCCCTGTAGTAGA
GGGTGAGCAAAATGTACAAAACTCCTGCCCTGGCAGACCCAACATTCTACTAAGGGATCTAGACAAAAAACAAAGAAATAAGTAAAATATACTTACTATATAGACTG
CTAGGTAGTGCGAAGTAACTAAGAAGAAAAATAGAGTAGGAGCCAAATTTGGTGGCTTATGCTTGTAATCACAGCACTTTGGGAGGCTGAGGCGAGGGGATCACTT
GAGCCCAGAAGTTCAAGACCAGCCTGGACAACGTAGCAAGATCCTATCTCTACAAAAAAGTAAATAAATTGGCCGGGCGTGGTGACTGCACCTGTATTCCCATGGAA
TTGGGAGGCCGAGGCAGGAGGATCACTTGAACGCAGGAGGTCAAGGCTGCTGTGAGCTATGATCATCAGTCTTGGCAACAGAGGGAGAACCTGTCTCTAAAAAAA
AAAAAAAAAAAAAAAAAAATTGAACAGGGAGGGGAATAAGGGGTGTGGGGAAGGGATGGGGTGCAGCATTAAATGGGCAGGCCTCTGGATGAGGTGGCTCAGG
CCAGCAATCCCAGCACTTTGGACAGATGACTTGAGTCCAGGAGTTTGAGACCAGCCTGGGCAATGTGGCAAAGCCCCATCTCTACAAAACAAAACAAAAAACAAAAA
GCAGATGTGGCACGCGCCTGTAGTCCCAGCTACTTCAGGGGCCAAGGCAGGAAGATTGCTTGAGCCTGGGAGGTTGAGGCTGCAGCGAGCTGAGATCACGCCACT
CCTGCATGACAGAGTGAGACTCTGTCTCAAAAAAAGAAAAAAGGGCAGGCCTCACGAAGGAGGTGTTGTTTGAGCAAAGCATGAATGTATATGTGAGCGAGGGAG
TGTGTGTGTGTGCACACGTGCGTGTGTCTCTCTCTTTCTCTCTGTGGCCACTTATCTATGTAAGGGTGTGTCTCTGCCCACTCCCCTCCCTTTCATCTTCCACATTCTTCA
GTGTCTTTCCTGTGACCTGCACTAACCATTTCAGAATGAGCCCCGTTATGGGGATGGACAAGGAGATCAAATCCTGACTCCAGGCCCTCACCAGCCCGGAGGGACTG
GGGTTGAGGCAGGGGCTGCTTGGAGTCCCAGAGGCAGTGGGTTGCGGGAGGTGGGTTCCCTATGTCCAGATTAGACACTCTGTCCCCCTCCCCTCCCCTAGGGTCG
CAGACGAACCTGAGAGAATCGGGGGACCTGAGGTCACAA 
Exon15
Intron 15
Exon 16
Intron 16
Exon 17
=  exonic sequence =  polypyrimidine tract =  putative PTB binding sites
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3.2.2 Conservation analysis of the identified putative PTB binding sites 
We then performed the analysis of the evolutionary conservation of the predicted PTB binding 
sites in MARK4 pre-mRNA by Clustal Omega. As reported in Figure 18, all the putative PTB 
binding sequences identified show a high conservation, between 60% to 100%, in human and 
mouse. Conversely, the overall conservation, in human and mouse, of the two introns is very 
low, supporting an effective functional role for the intron-embedded conserved sequences. 
 
 
Figure 18. Human-mouse conservation of putative PTB binding sites identified in MARK4 pre-mRNA. Stars 
indicate 100% conservation while the dashed line represents gaps included by the program to reach the best 
alignment score of the two sequences. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Homo sapiens     GTGAGCTCCGCGGGGATGGCAGGGGCAGGGCGGGGCGGGGGGCCGATGGGACCTAACCTG 
Mus musculus     GTGAGCTGCACCAGATGTGGGGTATGGGTGTGGGTGGGTGGAGGGGTGGGGCCTAACCTG 
                 ******* *.* .*.:  * .* .  .* * ***  ** **.  *.****.********* 
 
Homo sapiens     TCTTCCACTCTGCTCTGTCTCCTGTACCCCAACATTTCCTCTTCCTCC------------ 
Mus musculus     TCTTCTCTGCTTCGCTTCCTG---CACCTGACCTCTTGGTCCTCTGCACCCCCTGTCACC 
                 ***** .  ** * **  **     ***  *.*: **  ** **  *.             
MARK4 intron 15
MARK4 intron 16
Mus musculus    TGCCTC-AGGTGTAGG-TAAATCTCGTCACAGAGTAGC--CAAGGGTGCAGACCCAGCCA 270 
Homo sapiens    CTCTTC----TGTAAAATGGTTAT-----------AGTAATAACAATACCTGTCT--CCT 274 
                  * **    ****   *   * *           **    **   * *    *   **   Mus musculus    TGCCTC-AGGTGTAGG-TAAATCTCGTCACAGAGTAGC--CAAGGGTGCAGACCCAGCCA 270 
Homo sapiens    CTCTTC----TGTAAAATGGTTAT-----------AGTAATAACAATACCTGTCT--CCT 274 
                  * **    ****   *   * *           **    **   * *    *   **   
Mus musculus    TGCCTC-AGGTGTAGG-TAAATCTCGTCACAGAGTAGC--CAAGGGTGCAGACCCAGCCA 270 
Homo sapien CT T --- AAA GGT A ----------- TAAT CAA A CTGT T-- T 4
             * **    ****   *   * *           **    **   * *    *   **  
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3.3 Evaluation of PTB protein expression in glioma 
 
PTB belongs to the hnRNP protein family and it is reported to mainly induces skipping of 
alternative exons: overexpression is thus a prerequisite for its involvement in aberrant splicing in 
glioma. Indeed, several studies reported upregulation of PTB expression in glioma and the 
consequent overexpression of protein isoforms that undergo exon skipping (David et al., 2010).  
To evaluate PTB expression profile in our panel of glioma samples, in addition to 
undifferentiated and differentiated GBM CSCs we performed immunoblot experiments.  
 
3.3.1 PTB expression profile in glioma tissues and GBM CSCs 
Western blot analysis of PTB expression in the same tissue samples used for total MARK4 (see 
3.1.1) and MARK4L and MARK4S mRNA expression evaluation (Magnani et al., 2011), 
showed a significant overexpression of PTB in glioma samples compared to normal brain (p < 
0.001 at Wilcoxon test). Figure 19 shows a selection of representative astrocytoma and 
glioblastoma tissues as compared to normal brain. Moreover, the expression of PTB increases 
along with tumour grade and cellular de-differentiation, with the highest expression in GBM 
CSCs (mean values: A = 0.1, GBM = 0.3 and GBM CSCs = 0.7) (Figure 20A). In addition, PTB 
expression levels correlate with the relative increase of MARK4L expression, inferred from the 
MARK4L/MARK4S ratio, previously observed in the same samples (Magnani et al., 2011) 
(Figure 20B). 
 
Figure 19. Western blot evaluation of PTB protein expression in human normal brain and three representative 
astrocytomas (A) and glioblastomas (GBM). The PTB band of 57 kDa is apparent in astocytomas and much more 
intense in glioblastomas. GAPDH expression was used for normalisation. 
PTB
(57 kDa)
GAPDH
(35 kDa)
Normal brain Astrocytoma Glioblastoma
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Figure 20. PTB protein expression compared to MARK4L mRNA increment in all the glioma tissues and GBM 
CSCs investigated in this study. A) PTB protein expression in astrocytomas (A), glioblastomas (B) and 
glioblastoma-derived cancer stem cells (GBM CSCs) compared to normal brain (NB). Data are expressed as mean ± 
standard deviation of three independent experiments and PTB expression has been normalised on GAPDH protein 
expression. B) MARK4L/MARK4S mRNA ratio in astrocytomas (A), glioblastomas (GBM) and glioblastoma-
derived cancer stem cells (GBM CSCs) (adapted from Magnani et al., 2011).  
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3.3.2 Comparative expression of PTB and MARK4L in undifferentiated and 
differentiated GBM CSCs 
We have previously demonstrated that MARK4L increase in glioma tissues is directly 
proportional to tumour grade and cellular de-differentiation, and that GBM CSCs show a 
MARK4 expression profile similar to that of glioblastoma tissues and mouse neural stem cells 
(NSCs), with high levels of MARK4L and slightly detectable levels of MARK4S (Magnani et 
al., 2011). These evidences suggested a role for MARK4L in proliferation and for MARK4S in 
cell differentiation, respectively. To further support this hypothesis we analysed MARK4L 
protein expression in undifferentiated and differentiated NSCs and GBM CSCs. We highlighted 
that all subgroups of stem cells show high levels of MARK4L expression (Figure 21A). 
Moreover, both undifferentiated and differentiated GBM CSCs share similar MARK4L 
expression levels of MARK4L, while in NSCs MARK4L is undetectable by the 7
th
 day of 
differentiation (Figure 21A). 
We also analysed the expression of PTB in undifferentiated and differentiated GBM CSCs, to 
evaluate the role of this splicing regulator in gliomagenesis and in tumour cell differentiation. 
Western blot analysis of PTB revealed that GBM CSCs, both undifferentiated and differentiated, 
show high levels of PTB in accordance with the nearly exclusive expression of MARK4L 
(Figure 21B). 
 
 
 
 
 
 
Figure 21. PTB and MARK4L expression in undifferentiated and differentiated stem cells. A) MARK4L protein 
expression in undifferentiated and differentiated NSCs,070104 and 0627GBM CSCs; B) PTB protein expression in 
undifferentiated and differentiated GBM CSCs.  
 
A
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3.4 MARK4 minigene splicing assay  
 
To investigate the presence of functional active splicing regulatory sequences in the MARK4 
introns flanking the alternative exon 16, we constructed a splicing minigene. The minigene was 
realised by cloning in a mammalian expression vector the genomic sequences corresponding to 
exons 15, 16 and 17 in addition to IVS15 and IVS16. Firstly, we tested the MARK4 splicing 
minigene in both normal HEK293T and oligoastrocytoma G157 cell lines. Then, we generated 
serial deletions of the minigene which were transfected in both HEK293T and G157 cell lines 
aiming at to pointing out alterations in MARK4 splicing caused by the absence, in the minigene, 
of specific splicing regulatory elements and hence identifying the sequences involved in 
MARK4 alternative splicing.  
 
3.4.1 MARK4 wild-type minigene splicing assay 
We performed splicing minigene assays on the HEK293T and G157 cell lines, that have been 
selected for their expression of MARK4L and MARK4S. In particular, HEK293T show a 
MARK4 expression profile similar to that of glioma cell lines, with nearly exclusive expression 
of MARK4L and slightly detectable levels of MRK4S (Figure 22). 
 
 
Figure 22. Relative expression of MARK4L and MARK4S mRNA in HEK293T and G157 cell lines compared to 
human neural progenitor cells (HNPCs) (conventionally set as 1 and represented by an horizontal black line). 
 
 
This expression profile of MARK4 isoforms mRNA is concordant with PTB protein expression 
in these cell lines. As reported in Figure 23, both HEK293T and G157 cell lines show high levels 
of PTB expression, as expected given the embryonic nature of HEK293T and the cancer origin 
of G157 cells. 
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Figure 23. PTB protein expression in HEK293T and G157 cell lines. 
 
 
Transfection of wild-type MARK4 minigene in HEK293T and G157 cell lines and subsequent 
RT-PCR to evaluate minigene splicing, confirmed that the vector undergoes splicing that results 
in a band of 194 base pairs (Figure 24A). Sequencing of the band revealed skipping of exon 16, 
confirmed by the presence of the exon 15-17 junction, and thus highlighted that the minigene is 
converted in the MARK4L isoform by alternative splicing (Figure 24B). 
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Figure 24. MARK4 wild-type minigene splicing assay. A) Schematic representation of MARK4 wild-type minigene 
construct and RT-PCR of minigene splicing assay in HEK293T and G157 cell lines. B) Sequencing of the RT-PCR 
band of MARK4 wild-type minigene confirms the presence of MARK4 exons 15-17 junction. CMV, 
cytomegalovirus promoter; BGH, bovine growth hormone binding site; nt, nucleotides; bp, base pairs.  
 
 
 
3.4.2 Mutated MARK4 splicing minigene assays 
To evaluate the presence of active splicing regulatory elements in MARK4 minigene, we 
introduced serial deletions in the minigene splicing vector and then evaluated alterations in the 
splicing of the mutated minigenes. We focused our attention onto IVS15 and, in particular, the 
polyprymidine tract harbouring one of the putative PTB binding sites identified by bioinformatic 
analysis. We performed deletions of different portions of the polypyrimidine tract in IVS15 to 
assess the presence of functional regulatory motifs.  
We started deleting 87 nucleotides of IVS15 3’-end comprising the polypyrimidine tract and one 
of the putative previously identified PTB binding sites (MARK4 del87 nt). We then selectively 
deleted the PTB binding site included in the polypyrimidine tract (MARK4 delPTB) and the 3’ 
proximal region of intron 15 (MARK4 del IVS15 prox) to determine whether any of the splicing 
regulatory sequences involved in exon 16 skipping was represented by the canonical identified 
PTB binding site or by a different splicing motif (Figure 25A).  
Deletion of the last 87 nucleotides of MARK4 IVS15 (MARK4 del87 nt) turned out to foster 
exon 16 inclusion, confirmed by sequence analysis (Figure 25A and B), indicating the presence 
of a functional intronic splicing silencer (ISS) in this region. By contrast, deletion of the 
predicted PTB binding site (MARK4 delPTB) contained in this region did not affect minigene 
splicing, suggesting that PTB may bind to a non-canonical ISS (Figure 25A). To further 
elucidate the specific sequence involved in MARK4 alternative splicing we also deleted 32 
nucleotides (MARK4 del32 nt) comprising the putative PTB binding site in the polypyrimidine 
CMV
B
Exon 15
BGH
Exon 17
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tract of IVS15 and the 27 downstream nucleotides. Also this deletion did not modify the splicing 
of the MARK4 minigene. Interestingly, deep analyses of the MARK4 splicing minigene derived 
from deletion of these 32 nucleotides, revealed that the deletion reconstructed a specific 
sequence, TTTCCTCCTCC, that might be the candidate regulatory sequence involved in 
MARK4 alternative splicing. 
 
 
 
 
 
 
 
Figure 25. MARK4 deleted minigene splicing assays. A) Schematic representation of MARK4 deleted minigene 
constructs and RT-PCR of minigene splicing assays. B) Sequencing of the RT-PCR upper band of MARK4 obtained 
by MARK4 del87nt minigene splicing assay confirmed the presence of MARK4 exons 15-16 junction. CMV, 
cytomegalovirus promoter; BGH, bovine growth hormone binding site; nt, nucleotides; bp, base pairs.  
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3.5 MARK4 electrophorectic mobility shift assay 
 
To identify splicing regulatory factors bound to the 87 nucleotides deleted in the MARK4 del87 
nt minigene, we synthesised a biotinylated single strand riboprobe, corresponding to the deleted 
region, and performed electrophoretic mobility shift assay (EMSA) experiments. Incubation of 
MARK4 riboprobe with HEK293T total cell lysate, highlighted a shifted band derived from the 
binding of a splicing factor to the riboprobe (Figure 26, lane 2). As depicted in the Figure 26 in 
lane 3 the intensity of the shifted band is attenuated after addition of a large amount of non-
biotinylated MARK4 riboprobe as binding competitor, confirming that the observed shift derives 
from a specific RNA-protein interaction. Preliminary mass spectrometry experiments seem to 
confirm the presence of PTB in the shifted band. 
 
 
 
Figure 26. MARK4 EMSA experiments. Lane 1: only MARK4 biotinylated RNA was loaded allowing to establish 
the position of the unshifted band. Lane 2: MARK4 biotinylated RNA incubated with HEK293T protein extract was 
loaded. A shifted band is observed attesting the binding to MARK4 mRNA of a putative target protein. Lane 3: 
MARK4 biotinylated RNA incubated with HEK293T protein extract and 200-fold molar excess of MARK4 
unlabeled RNA as binding competitor was loaded. The shifted band is observed, but with lower intensity, 
demonstrating that the shift results from specific protein-RNA interaction. 
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The differential expression of MARK4L and MARK4S in human normal and transformed 
tissues, and in particular in the Central Nervous System (CNS), suggests that the expression of 
the two MARK4 isoforms is tissue-specific and regulated according to distinct developmental 
stages. This implies that the two isoforms do not have fully overlapping functions, and that 
isoform-specific activities are required in different cell types and conditions. Indeed, the findings 
on the predominance of MARK4L in neural progenitors and its upregulation in glioma (Beghini 
et al., 2003; Magnani et al., 2011), coupled to the observed duplication of the MARK4 gene in 
glioma cell lines (Roversi et al., 2006), imply a role for this isoform in cell proliferation. The 
MARK4S isoform appears instead involved in neural differentiation given its expression in 
normal brain and terminally differentiated neurons (Moroni et al., 2006). Moreover, glioma 
tissues are characterised by an altered MARK4L/MARK4S ratio that appeared directly 
correlated to tumour grade and cell de-differentiation (Magnani et al., 2011). A high MARK4L 
expression, associated with slightly detectable levels of MARK4S also labelled glioblastoma-
derived cancer stem cells (GBM CSCs) and mouse neural stem cells (NSCs), suggesting that the 
balance between the two MARK4 isoform may be thinly regulated during neural differentiation 
and might be subverted in gliomagenesis (Magnani et al., 2011).  
The demonstrated absence of genomic mutations that could favour the expression of MARK4L 
to the detriment of MARK4S in glioma, prompted us to hypothesise alterations at the post-
transcriptional level that may account for the observed altered ratio of MARK4 isoforms in 
glioma. A prerequisite to assume the involvement of post-transcriptional alterations is the 
observation of altered relative expression of the two isoforms in the absence of differences in the 
overall expression of the gene. We thus performed real-time quantification of MARK4 total 
mRNA to point out possible differences in gene transcription in the same glioma samples used 
for MARK4L and MARK4S mRNA quantification. No significant differences in the expression 
of MARK4 total mRNA have be highlighted in astrocytomas, glioblastomas and GBM CSCs, 
neither among subgroups nor between tumour samples and normal brain. This recent evidence 
merges with the previous data on the altered ratio between the two MARK4 isoforms in 
supporting the working hypothesis of this study on post-transcriptional alterations of MARK4L 
and MARK4S expression in glioma. 
We thought that alternative splicing could be the most likely mechanism responsible for the 
aberrant MARK4L/MARK4S ratio in glioma. Indeed, alternative splicing is not only the most 
effective mechanism to generate proteome diversity from a restrict number of genes, but also a 
frequent target of alterations in cancer (Venables 2004; Ghigna et al., 2008). Alternative splicing 
is particularly exploited in the CNS where protein isoform expression is fine tuned during 
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neuronal development and in different brain regions to achieve high specific functions 
(Grabowski and Black, 2001). The intrinsic flexibility of alternative splicing enables the thinly-
regulated expression of specific isoforms, often with divergent functions, according to 
developmental stages, cell signalling and reprogramming of energetic metabolism of tumor cells. 
Cis- and trans-acting factors are the key players in the recognition of weak splice sites and 
mutations in enhancer and silencer sequences, or alterations in the expression/activation of SR 
and hnRNP proteins, have been heavily associated with cancer as either causative, modulating or 
compensatory mechanism (Venables 2004; Ghigna et al., 2008, Hanahan and Weinberg, 2011). 
Specific splice variants are commonly found enriched in cancer tissues compared to normal ones 
(Singh et al., 2004; Zhou et al., 2003). In these cases, enriched in aberrantly spliced isoforms, the 
spliced genes are not mutated, indicating that the defects imply a change in the nuclear 
environment that regulates splice site choice (Grosso et al., 2008). Several studies reported that 
the up-regulation of different splicing factors in tumours, including gliomas, affects the splice 
site selection. As a consequence, the generation of splice variants encoding protein isoforms, 
which are advantageous to transformed cells, are positively selected during tumour progression 
(Grosso et al., 2008). In particular, the inappropriate expression of isoforms produced by exon 
skipping, like MARK4L, is generally favoured in cancer as a consequence of overexpression of 
negative regulators of alternative splicing belonging to the hnRNP protein family (He and Smith, 
2009).  
We thus performed a bioinformatic analysis of putative binding sites for hnRNP proteins in 
introns flanking MARK4 alternative exon 16. Several putative hnRNP binding sites have been 
identified by SFmap and SpliceAid and most were reported to be involved in brain development 
and related pathologies (Grabowski and Black, 2001). The identified putative binding sites for 
the Polypyrimidine-Tract Binding protein (PTB) aroused our interest for the position of its 
binding sites in MARK4 introns and for the well established role of this splicing factor in neural 
differentiation and glioma (Boutz et al., 2007; David et al., 2010). Indeed, the switch from PTB, 
manly expressed in neural progenitors and glial cells, to its neuronal homologue nPTB drives the 
differentiation along the neuronal lineage (Boutz et al., 2007). PTB and nPTB expression profile 
and behaviour thus appear very similar to that of MARK4L and MARK4S respectively. 
Moreover, immunohistochemistry on mouse brain revealed a PTB localisation in developing 
brain overlapping that of MARK4L. The two proteins appear highly expressed in the embryonic 
ventricular and adult sub-ventricular zones, well known regions of neurogenesis (Suckale et al., 
2011; Magnani et al., 2011). We thus hypothesised that PTB may favour the expression of the 
MARK4L isoform during neural development, setting up a MARK4 splicing profile that 
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supports cell proliferation and the maintenance of an undifferentiated phenotype. The switch off 
of PTB expression in committed progenitors may thus address the expression of MARK4S in the 
context of a nPTB-dependent neuronal-specific splicing pattern. Bioinformatic analysis revealed 
the presence of three putative PTB binding sites in both introns flanking the alternative exon 16, 
two in IVS15 and one in IVS16. The position of these binding sites is consistent with all the 
proposed mechanisms of PTB-induced alternative splicing (Spellman and Smith, 2006). Indeed, 
the putative PTB binding site in MARK4 intron 15 more proximal to exon 16, is embedded in a 
polypyrimidine rich sequence, that represents the ideal environment for PTB action. PTB may 
thus bind to this site with high affinity, in competition with the splicing factor U2AF65, leading 
to inhibition of the 3’ splice site recognition. As regards the other two putative PTB binding sites 
identified by bioinformatic analysis, they may cooperate with the high affinity binding site in the 
polypyrimidine tract and induce exon 16 skipping by polymerisation along introns and exon 16 
to mask splicing sites and enhancer elements favouring exon inclusion. Alternatively, PTB 
binding at adjacent introns may force conformational changes in the pre-mRNA that bring in 
close proximity exons 15 and 17 with concomitant looping out of exon 16.  
Additional support on a possible functional role of identified PTB binding sites comes from 
sequence conservation analysis. It has been reported that 77% of alternatively spliced exons are 
surrounded by conserved intronic sequences, compared to only 17% of non-alternatively spliced 
exons. Furthermore, the conservation picks at specific short sequences frequently represented by 
splicing enhancers and silencers (Sorek and Ast, 2003). The high conservation between human 
and mouse of the putative PTB binding sites identified in MARK4 IVS15 and IVS16 point to a 
functional role of these sequences in MARK4 alternative splicing.  
PTB has also been implicated in the deregulation of alternative splicing in several pathologies, 
including glioma. The thinly tuned expression of this splicing regulator is frequently subjected to 
alterations that lead to the aberrant expression of associated protein isoforms. PTB has been 
reported to be overexpressed in glioma, with expression levels correlating with tumour grade 
(McCutcheon et al., 2004; Cheung et al., 2006; Cheung et al., 2009). In our panel of glioma 
samples, including astrocytomas, glioblastomas and GBM CSCs, PTB is overexpressed, with 
expression levels directly correlated with MARK4L mRNA expression, and thus with tumour 
grade and cell de-differentiation (Figure 20). These evidences strengthen the role of PTB in 
MARK4 alternative splicing: in physiological conditions low levels of PTB may favour the 
expression of MARK4S and hence direct and maintain the correct differentiation status of neural 
progenitors and derived cells, while in glioma, PTB overexpression, and the consequent 
expression of MARK4L to the detriment of MARK4S, may enhance the maintenance of the 
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undifferentiated phenotype of transformed cells, endowed with a high proliferation rate, needed 
to support tumour growth and spread. A role of PTB in stem cells proliferation and 
differentiation has been recently highlighted by knockout experiments on mouse embryonic 
fibroblasts, in which PTB absence impairs proliferation and differentiation (Shibayama et al., 
2013; Suckale et al., 2011). We have demonstrated that PTB overexpression also characterises 
GBM CSCs and is not downregulated after induction of differentiation, supporting a 
fundamental role of this splicing factor in cancer cell proliferation. We also pointed out the 
intriguing coincidence, that also MARK4L is highly expressed in both undifferentiated and 
differentiated NSCs and GBM CSCs. Furthermore, while in normal stem cells MARK4L 
expression is switched off since the 7
th 
day of differentiation, in GBM CSCs MARK4L is 
maintained overexpressed also upon differentiation. Together with the expression of PTB in 
GBM CSCs, these data let us hypothesise that PTB overexpression is an early event in glial cell 
transformation and that, in keeping with MARK4L overexpression, it is part of a stemness-
expression program that is aberrantly reactivated in glioma.  
The definition of cis- and trans-acting factors involved in alternative splicing of a specific pre-
mRNA necessarily passes through the association between the splicing factor and the putative 
binding sequence. To reach this goal we used minigene splicing assays which are diffuse and 
reliable tools for the study of alternative splicing. We encountered several difficulties in the 
construction of a functional splicing minigene, probably due to the presence of long stretches of 
repeated nucleotides, adenine in particular, in the sequence to be cloned. These repetitive 
sequences made the vector unstable upon bacteria transformation and in most cases the cloned 
fragment appeared to be partially or completely excised from the vector. We tried several 
conditions of transformation and many bacterial strains and we finally succeeded in obtaining a 
complete and functional MARK4 minigene vector, even if the efficiency was repeatedly low. 
The wild-type MARK4 minigene appeared to be correctly processed by alternative splicing 
producing a nearly 100% exon 16 skipping in both HEK293T and oligoastrocytoma G157 cell 
lines, consistent with the high expression of PTB in these cell types. Indeed, both HEK293T and 
G157 cell lines show physiologically low levels of MARK4S expression associated with high 
levels of MARK4L mRNA and PTB protein expression. To identify binding sequences involved 
in MARK4 alternative splicing we performed serial deletions in the MARK4 minigene, focusing 
our attention on intron 15 3’-end that harbours the polypyrimidine tract, considered to be a 
suitable candidate to contain a functional PTB binding motif. Deletions were designed to avoid 
excision of the branch site, predicted to be localised upstream the polypyrimidine tract, and to 
maintain the acceptor splice site at the intron 15-exon 16 boundary, as to prevent intron retention 
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and preserve exon 16 recognition. We identified a regulatory element of MARK4 alternative 
splicing in the last 87 nucleotides of intron 15, as deletion of this region determines exon 16 
inclusion in the minigene splicing assay. As can be noted in Figure 25A, the reversion of 
alternative splicing of the minigene from MARK4L to MARK4S was not complete, as two RT-
PCR bands are visible, suggesting the cooperation of multiple factors in MARK4 alternative 
splicing. This finding may be accounted by the huge complexity of the splicing process. Since 
the deletion of the putative PTB binding site, comprised in these 87 nucleotides, did not affect 
alternative splicing, we are considering the possibility that PTB binds to a non canonical site, as 
demonstrated for other PTB-dependent alternative splicing (Ladd and Cooper, 2002). 
We thus decided to perform electrophoretic mobility shift (EMSA) assay to definitely 
demonstrate the interaction between MARK4 pre-mRNA and splicing regulatory factors. We 
demonstrated an interaction between the polypyrimidine tract of IVS15 and protein factors, but 
EMSA experiments were not conclusive in the definition of the specific splicing factor involved 
in MARK4 alternative splicing. Mass spectrometry experiments, on the shifted band obtained by 
EMSA, are ongoing with the aims of: i) assign to PTB a definitive role in MARK4 splicing 
modulation and/or ii) identify other splicing regulators associated with MARK4 mRNA affecting 
its alternative splicing. Preliminary results seem to confirm the presence of PTB in the shifted 
band. 
In conclusion by this study we tried to go to the root of the imbalance between the two MARK4 
isoforms observed in glioma by studying MARK4 alternative splicing as the causative 
mechanism. Suggestive bioinformatic evidences have been achieved and pieces of experimental 
evidence have been obtained, notwithstanding the experimental pathway is not yet closed. 
Should splicing factors involved in MARK4 alternative splicing be definitely identified, this 
novel knowledge will also be instrumental to insert the expression of this kinase in a specific 
pathway of cell signalling, as was the case for pyruvate kinase that has been linked to c-myc and 
related pathway in glioma (David et al., 2010). Moreover, specific cis-acting elements, 
demonstrated to regulate MARK4 alternative splicing, will be ideally target of molecular therapy 
and might be exploited to revert the balance between the two MARK4 isoforms in glioma. 
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Perspectives 
 
In light of the achieved results we are pursuing the following experiments to confirm the role of 
PTB in MARK4 alternative splicing: 
 Mass spectrometry analysis of the shifted band obtained by EMSA experiments. 
 Electrophoretic mobility shift assay with MARK4 riboprobe mutated in the hypothetical 
splicing factor binding site.  
We are also planning further experiments aimed at  
 Downregulating PTB expression by siRNA and then monitoring MARK4 isoforms 
expression byminigene splicing.  
 Carrying on RNA immunoprecipitation experiments to confirm the interaction between 
MARK4 pre-mRNA and identified splicing factors.  
 Carrying on chromatin immunoprecipitation experiments to identify alterations in 
histone modifications that may favour PTB-dependent splicing of MARK4 pre-mRNA 
in glioma. 
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